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ABSTRACT 
Christina Cordero: The Association Between Prenatal and Neonatal Complications and Autism 
Spectrum Disorder in the Child   
(Under the direction of Julie Daniels) 
The documented prevalence of autism spectrum disorder (ASD) has increased in recent 
years. ASD is a heterogeneous group of neurodevelopmental disorders with multiple factors 
involved; however, specific causal factors remain relatively unknown. Previous studies have 
shown associations between prenatal and neonatal complications and neurodevelopmental 
disorders. However, they are limited by small samples sizes, the use of administrative data, or by 
not accounting for confounding or interaction.  
To address these limitations, this study utilized data from the Study to Explore Early 
Development, a population-based case-control study with data from medical records and 
maternal report collected from six study sites located in the United States. A clinical evaluation 
classified each child as meeting criteria for ASD (ASD n=698), having a developmental disorder 
or delay without traits of ASD (DD n=887), or as a population control (POP n=979). In Aim 1, 
we evaluated the association between maternal diabetes (n=246) and hypertensive disorders 
(n=386) and ASD, two common complications of pregnancy. In Aim 2, we evaluated the 
association between neonatal jaundice (n=1239) and ASD, which is variably associated with 
ASD in previous literature. In our analysis, we controlled for confounding and assessed whether 
the observed associations were modified by other factors such as maternal body mass index and 
gestational age. We evaluated how associations varied when comparing ASD to POP versus DD 
to POP, allowing us to determine if associations are specific to ASD. In Aim 1, we found an 
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association with maternal hypertensive disorders and ASD (aOR=1.67[95% CI 1.25, 2.23]), and 
similarly with DD; but no association with diabetes and ASD. In Aim 2, neonatal jaundice was 
associated with ASD in infants born 35-37 weeks (aOR=1.83[95% CI 1.05, 3.19]) and also with 
DD, but not in infants born ≥38 weeks.  
Our findings suggest that maternal hypertensive disorders and neonatal jaundice are 
associated with ASD. Future studies should investigate the role of timing and severity of these 
disorders in association with ASD. These results can help identify children at higher risk of 
developmental disorders for whom developmental screening at younger ages may allow for 
identification at younger ages and potentially earlier intervention. 
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CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
A. Introduction 
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental 
disorders characterized by impaired socialization and communication, and repetitive and 
stereotyped interests and behaviors. The documented prevalence of ASD has increased in recent 
years; ASD affects one in 68 children, and 1 in 42 boys, aged 8 (1). Causes of ASD remain 
unknown, but it is believed to be a complex disease involving both genetic and environmental 
factors (2, 3).  Recent studies provide evidence for gestation and the early postnatal period as 
sensitive time windows for ASD. One study suggests that formation of the cortical layer in utero 
may be disrupted among children with ASD (4). Other studies have shown that deficits in eye 
contact and ability to follow the parent’s eye gaze (joint attention) are present in infants less than 
a year old (5, 6).  
Perinatal complications have been associated with an increased risk of developmental 
difficulties in children including ASD (7-13). Several studies have reported associations with the 
most common prenatal complications (maternal diabetes and hypertension) and most common 
neonatal complication (neonatal jaundice) and ASD (14-18). We hypothesize that the changes to 
the perinatal environment associated with these conditions through pathways such as increased 
inflammation and oxidative stress, over-nutrition (with diabetes) and nutritional insufficiencies 
and growth restriction (with hypertension) (19), and increases in potentially neurotoxic 
substances (12, 20-22).  This may lead to alterations in gene expression patterns or neural 
connections and synaptic development that can have a deleterious effect on brain development 
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and lead to ASD (23-25). More recently, observational studies have begun evaluating these 
specific conditions, but have been limited by: 1) the sample size to study a rare exposure and rare 
outcome, 2) the exposure and outcome definitions are obtained from a secondary source without 
confirmation, and 3) specific complications are not modeled independently, but instead are 
modeled in aggregate with other conditions, without properly accounting for confounding or 
interaction.  
We address these limitations from previous studies utilizing a large, community-based, 
case-control study, the Study to Explore Early Development (SEED). We evaluate the 
association of the most common complications in pregnancy, maternal diabetes and 
hypertension, with ASD, adjusting for confounding and assessing for interaction by body mass 
index (BMI). We also evaluate the association of the most common complication in the neonatal 
period, neonatal jaundice, with ASD, adjusting for confounding and assessing for interaction by 
gestational age.  
SEED is the largest study of children with ASD in the United States to-date and provides 
the optimal data to evaluate these relationships (26). SEED was designed to identify etiological 
risk factors for ASD and collected data on potential risk factors from multiple sources, including 
prenatal and neonatal medical records and maternal interview and questionnaires. SEED has also 
carefully characterized ASD through in-depth clinical assessment and allows comparison of 
children with ASD to children with other developmental delays (DD) and a population-based 
sample (POP) of children of the same age and location from the community. The ability to also 
compare associations among children with DD to POP children allows us to determine the 
specificity of any observed associations. We take advantage of this large, rich existing data to 
address the following specific aims:    
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B. Specific aims 
Specific Aim 1: To examine the association between prenatal complications and 
autism spectrum disorder in the child. The most common complications in pregnancy, 
diabetes and hypertension, have been observed in relation to the development of ASD in the 
child. We expand upon recent findings to evaluate whether this association was specific to ASD, 
or also observed with DD. We also assessed the complex role of BMI and whether having both 
conditions increased risk, as multiple conditions can confound or modify these associations, or 
act as mediators on the causal pathway.   
Specific Aim 1a: To examine the association between diabetes in pregnancy and autism 
spectrum disorder in the child.  The classification of mothers with diabetes in pregnancy 
includes those with a new diagnosis of gestational diabetes or diabetes that was diagnosed prior 
to pregnancy and continued into their pregnancy.   
Hypothesis:  We hypothesize that maternal diabetes during pregnancy will be positively 
associated with ASD in the child.  Rationale: Diabetes affects maternal inflammatory response, 
oxidative stress, fetal nutrition, and fetal metabolism, all which may affect fetal 
neurodevelopment. 
Specific Aim 1b: To examine the association between hypertensive disorders in 
pregnancy and autism spectrum disorder in the child. Hypertensive disorders in the mother are 
classified as either a diagnosis of hypertension prior to pregnancy with elevated blood pressures 
during pregnancy, or as a hypertensive disorder that was induced by pregnancy, including 
pregnancy induced hypertension, preeclampsia, eclampsia and HELLP syndrome. 
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Hypothesis: We hypothesize that hypertensive disorders in pregnancy are positively 
associated with ASD in the child. Rationale: Maternal hypertension is associated with reduced 
placental perfusion, changes in fetal oxygen and nutrient consumption, and inflammation and 
oxidative stress impacting the neurodevelopment of the fetus. 
Specific Aim 2: To examine the association between neonatal complications and 
autism spectrum disorder in the child. We evaluated the association between neonatal 
jaundice and hyperbilirubinemia in association with the development of ASD in the child, and 
assessed for interaction with gestational age at birth. We assessed the strength of the association 
by the method used to define jaundice. We used bilirubin measures from the medical record to 
assess if the association is stronger among infants that present with more severe jaundice. We 
evaluated if this association was specific to ASD, or also observed with DD. 
 Hypothesis: We hypothesize that jaundice and hyperbilirubinemia will be positively 
associated with ASD in the child. Rationale: Neonatal jaundice may be indicative of high levels 
of bilirubin that may have toxic effects in the brain, particularly in early development.  
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CHAPTER 2. BACKGROUND 
A. The etiology of autism spectrum disorder is relatively unknown 
Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders that are 
typically diagnosed in early childhood, usually before the age of three, and characterized by 
impaired social interactions, impaired verbal and non-verbal communication, and restricted 
interests and repetitive behavior patterns. ASD affected one in 68 children aged 8 in 2010, with a 
higher prevalence of 1 in 42 observed in boys, according to the most recent estimates from the 
Centers for Disease Control and Prevention (CDC) (1). The documented prevalence of ASD has 
increased dramatically over the past few decades, in part because of better diagnosis and 
increased awareness (27, 28). A child with ASD requires constant and long-term care from 
family members and healthcare professionals and therefore carries a large emotional and 
financial burden. It is estimated that a child with ASD incurs an additional $17,000 per year in 
medical costs compared to a child without ASD (29) and additionally requires intensive 
behavioral interventions estimated at $40,000 to $60,000 per child per year (30). Despite the 
large burden of ASD, little is known about its causes. Early studies in families estimated that 
about 90% of ASD were heritable (31-34), yet more recent estimates suggest the heritability to 
hover around 50% (2, 3). Earlier studies do not seem to distinguish between a condition being 
heritable versus genetic, using these terms interchangeably while heritable diseases can have 
environmental components. Few gene loci have been consistently identified in association with 
ASD (2), leading researchers to believe that ASD may more likely be heritable due to shared 
environment versus there being a single gene that is responsible. In the last few decades, 
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etiological research focus has shifted to investigate the interaction between genes and 
environment, where environmental factors trigger or mediate ASD phenotypes in individuals that 
are genetically vulnerable (35). Twin studies are often used to evaluate the influence of genetic 
and environmental factors on individuals. The largest population-based twin study to date found 
that shared environmental factors account for 55% of the variance of risk for ASD among twins, 
while genetic factors only account for approximately 37% (2). A common theory is that multiple 
causes are likely to operate in the etiology of ASD, which can include several combinations of 
genes and environmental factors, broadly defined as any factor that is not genetic (9). By 
definition, this would classify ASD as a complex disorder where multiple factors contribute to its 
development. Epidemiological investigations are needed to determine which specific factors are 
involved.  
B. Critical window of brain development   
The brain begins to develop in utero and continues through early childhood (36).  Brain 
imaging studies using MRI have found distinct differences in brain volume (having more gray 
and white matter) and atypical growth patterns in early life of children with ASD (37, 38). 
Etiologic studies of ASD have started to focus on events during the prenatal and perinatal period, 
as this is known to be of critical importance to brain formation and development. A study 
recently published in the New England Journal of Medicine identified that areas of the prefrontal 
and temporal cortex, which begins to develop in utero, displayed disrupted growth and layer-
specific neuronal differentiation in children with ASD (4). These results support findings from an 
earlier brain autopsy study that reported abnormalities in the structure of the frontal and temporal 
cortex in individuals with ASD (39), emphasizing the importance of conditions that can impact 
early brain development (39-42). Clinical studies have also shown early developmental 
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differences in infants who are later identified to have ASD. One study found that infants have 
eye gaze deficits characteristic of ASD as early as 2-6 months of age (6), suggesting early 
deviation in brain development. Another study further reported decreased joint attention 
initiation in infants 8-12 months that later develop ASD (5).    
C. Environmental exposures during the prenatal and neonatal period   
A number of prenatal exposures are associated with an increased risk of the child 
developing ASD. Exposures such as maternal smoking during pregnancy (43), maternal 
medication use and exposure to infections (44-49) and related complications such as threatened 
abortion before 20 weeks (50, 51), bleeding during pregnancy (43), and intra-uterine growth 
retardation (43, 50, 52, 53), have all been associated with an increase risk in ASD. Obstetric 
factors and indicators of poor neonatal health such as preterm birth (43, 46, 52-58), low birth 
weight (43, 50, 53, 59), and cesarean section (43) have also been associated with ASD.  
Yet, results across studies have been inconsistent and vary based on study design and 
methodology. Many studies have grouped multiple complications of pregnancy, labor, and the 
neonatal period together to create an overall obstetric suboptimality score (OSS), which has also 
been associated with an increased risk in ASD (60, 61). Others have examined specific 
complications of pregnancy, but have not presented results adjusted for confounding (58, 62). 
Recent studies have reported maternal metabolic conditions to be associated with ASD. Specific 
factors such as high body mass index (BMI) (12, 63-65), maternal weight gain (35), hypertensive 
disorders (12, 43, 66), and diabetes (12, 35, 64, 67) were included in these studies. However, 
inferences are limited due mainly to small sample sizes and possibility of bias. For example, 
many studies have not adequately adjusted for confounding—some adjust for mediators on the 
pathway to the outcome while others may not have data on covariates and simply report crude 
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measures (43, 52, 68). Nonetheless, early results from these studies suggest these conditions may 
be important and warrant more rigorous investigation.  
Diabetes and hypertension, the two most common complications in pregnancy, can 
impact the development of the fetus. The pathogenicity of these conditions in relation to ASD 
include the role of obesity on endogenous hormones such as leptin (69-72) and testosterone (64, 
73, 74), the effect of inflammation and oxidative stress on the fetus (75, 76), and a difference in 
maternal nutritional stores such as folic acid (77, 78) and fatty acids necessary for brain 
development such as docosahexaenoic acid (DHA; 79) (see Figure 2.1). Table 2.1 describes 
studies that have evaluated the association between diabetes or hypertension in the mother and 
the development of ASD in the child. These are further discussed in Section D and E, which 
describe in detail the role of maternal diabetes and hypertension on the early neurodevelopment 
of the child.  
Several exposures during the early postnatal period have been shown to affect 
neurodevelopment. Events during birth, such as labor complications (80-82), hypoxia (83-87), or 
low Apgar score (88-92) have been implicated as causal factors for psychiatric or 
neurodevelopmental disorders. Being born preterm (86, 93), with low birth weight or small for 
gestational age (94, 95), has also been associated with developmental delays or disorders. In 
infancy and early childhood, toxic exposures such as lead (96-98), iron deficiency anemia (99, 
100), or inflammatory responses to infections also affect brain development (101-104). Some of 
these birth outcomes and neonatal exposures have also been associated with an increased risk of 
ASD, such as Apgar score or small for gestational age (43, 52), preterm birth (52, 53, 71, 105), 
asphyxia and hypoxia (105), and congenital anomalies (52, 71, 106).  
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Insufficient studies have been conducted to evaluate the role of neonatal complications 
with ASD. Most studies to date include all prenatal, obstetric, and neonatal complications under 
one category (i.e. obstetric complications or obstetric suboptimality) or in combination of 
different complications in the same statistical model, adjusting for all factors in each reported 
measure even if they are not confounders. Few studies have analyzed the role of neonatal 
jaundice independently with appropriate assessment of confounding. Because jaundice is not 
typically reported in the birth record, exposure assessment in previous studies has relied on 
maternal report or access to some medical records. Results from these studies, shown in Table 
2.2 and discussed in Section F, are difficult to interpret due to limitations with inadequate sample 
sizes, inappropriate selection of comparison groups, differing definition of jaundice, and 
potential for bias by not adjusting for confounders or assessing for interaction with gestational 
age. This study addresses these limitations through use of the SEED data set.  
    
1
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Figure 2.1. Mechanistic pathway for diabetes and hypertension in pregnancy and fetal neurodevelopment 
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D. The role of diabetes in pregnancy on neurodevelopment   
Gestational diabetes (GDM), defined as any degree of glucose intolerance with onset 
during pregnancy, is one of the most common complications during pregnancy. The Agency for 
Healthcare Research and Quality pooled data from different studies to estimate a prevalence of 
6- 7% of pregnancies complicated by GDM, with a range of 1 to 25% depending on 
sociodemographic factors (15, 16). Screening for GDM occurs during 24-28 weeks of gestation, 
or earlier for women with clinical characteristics consistent with high risk of GDM (107). GDM 
is often difficult to distinguish from type II diabetes mellitus (T2DM) as T2DM can go 
unrecognized until the woman receives medical care during pregnancy. Accounting for diabetes 
existing prior to pregnancy, approximately 10% of pregnancies are complicated by these 
disorders (108). With the rise in obesity, these estimates are increasing (109).   
Changes in insulin production and glucose metabolism normally occur during pregnancy 
to promote fat storage to sustain the growing fetus and to prepare for lactation (110). Fatty acids 
are also necessary for synapse formation during fetal brain development, with changes in fatty 
acid availability directly affecting neuronal pathways (111). An imbalance of insulin and glucose 
levels can make the body insulin resistant. Insulin resistance induces dyslipidemia and chronic 
inflammation in adipose, muscle, and liver tissue detected by the presence of inflammatory 
markers (112). Many of these inflammatory markers have been shown to cross the placenta and 
enter fetal circulation (22, 110, 113-115). Fetal brain development can be disrupted by the 
presence of inflammatory markers that cross the placenta and affect neural pathways and gene 
expression. In animal models, increased levels of maternal inflammatory markers result in 
offspring with seizures, impairments in learning and cognitive development, and abnormalities in 
hippocampal regions (21, 22, 116, 117). Studies in children with ASD have found increased 
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markers of inflammation and oxidative stress as well as lipid mediators in the blood, all of which 
can cross the blood-brain barrier and affect neurodevelopment (118-122). A recent study using 
lymphoblastoid cell lines obtained from children with ASD compared with their typically 
developing siblings found a significant increase in cell necrosis when exposed to oxidative and 
nitrosative stress (123).  
Additionally, maternal insulin resistance may adversely affect fetal development, 
particularly if the fetus develops hyperglycemia and increases insulin production due to the 
mother’s hyperglycemic state (124). Mothers with diabetes often give birth to macrosomic 
infants, increasing the risk for obstructed labor, perinatal hypoxia-ischemia, and birth injury 
(125). Diabetic mothers are also more likely to suffer from placental insufficiency resulting in 
fetal growth restriction, which can adversely impact brain development (126, 127).  
Fetal hyperinsulinemia can also lead to an increase in fetal metabolism and oxygen 
consumption, resulting in hypoxia of the uterine tissue and if prolonged–fetal iron deficiency, 
which has been associated with behavioral and developmental disorders (128-131). The insulin-
induced high glucose uptake may also cause relative cellular hypoxia in the in utero environment 
(132, 133). Clinical studies have also shown that maternal insulin resistance during pregnancy is 
associated with deficits in fine and gross motor function in the child, as well as with language 
impairments, low verbal IQ, greater inattention and hyperactivity, and poorer cognitive function 
(134-140). Maternal diabetes during pregnancy has also been associated with neonatal 
complications such as congenital anomalies (141, 142) and neonatal jaundice (143).  
 Several epidemiological studies have reported positive associations between maternal 
diabetes and ASD (60, 62, 68, 144). However, others have not reported statistically significant 
associations with ASD (12, 43, 52, 61, 71). These studies, described in Table 2.1, appear to be 
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inconclusive due to small numbers of exposed cases and potential bias from study design and 
statistical modeling approach. There is also great variation in the assessment of diabetes and 
outcomes that may have led to misclassification and impacted study results. 
E. The role of hypertension in pregnancy on neurodevelopment   
Like diabetes, maternal hypertension may exist prior to pregnancy, develop during the 
pregnancy, or be associated with other complications such as preeclampsia, eclampsia, or 
hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. Preeclampsia affects 
about 3% of pregnancies while all hypertensive disorders complicate 5-10% or pregnancies (17, 
18, 145). These rates have been increasing in the past few years, likely attributed to the rise of 
obesity and maternal age at time of conception (145). As with diabetes, hypertension in 
pregnancy can produce a low-level continuous state of inflammation in the fetus that can cause 
brain damage, even in the absence of hypoxia (146). In fact, because blood pressure is 
independently related to plasma insulin, many of the adverse fetal effects from maternal 
hypertension are similar to those from diabetes (147).  
Hypertension during pregnancy can result in reduced placental perfusion, limiting 
nutrients and iron to the fetus, and typically results in intrauterine growth restriction, preterm 
delivery, and infants that are small for gestational age (20, 148-151). Hypertensive disorders 
have also been reported to cause asphyxia of the fetus (20, 152). Hypoxia-ischemia while in 
utero has shown the strongest association with brain injury (153-156). Both intrauterine growth 
restriction and asphyxia are associated with altered brain development and have been associated 
with several neurodevelopmental disorders (8, 105, 157-159). Conditions of fetal hypoxia and 
fetal iron deficiency are often present together when the mother is hypertensive, and has been 
associated with specific changes in the formation of the hippocampus as well as broad changes in 
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neurodevelopment (130, 131). Previous studies have reported an increased risk of several 
developmental disorders and delays with hypertensive disorders during pregnancy (160-162). 
Positive associations have also been reported between hypertension in pregnancy or 
preeclampsia/eclampsia and ASD (12, 67, 68, 71, 163).  
While obstetric suboptimality scores (OSS) that include diabetes and hypertensive 
disorders in combination with a variety of problematic obstetric conditions have been associated 
with ASD, it is necessary to study each exposure apart from the other factors. Most of the studies 
to date (Table 2.1) included maternal diabetes and hypertension along with all other prenatal and 
perinatal complications in association with ASD, without accounting for the other conditions.  
This may be because they lacked sufficient data or the large sample size required to have 
sufficient power to assess both a rare exposure and a rare outcome. Further, many of these 
studies only have data from one source that does not include information on the timing or 
severity of disease.  
To address these limitations and those previously discussed in Section D, we investigate 
the association between maternal diabetes and hypertension with ASD in SEED. SEED is a large 
multi-site case-control study with detailed data on ASD and perinatal conditions, as well as 
important covariates related to maternal characteristics and health history. Utilizing SEED, we 
can study rare exposures such as maternal diabetes and hypertensive disorders independently, 
and also subclassifications of these conditions based on onset. We are also able to assess for 
interaction with BMI and evaluate the specificity of this association by comparing it to that with 
DD. 
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Table 2.1. Summary of studies that have looked at the association between diabetes or hypertension in pregnancy and ASD 
First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
J. Piven, 1993 
(61) 
53 autistic probands 
and their 63 siblings 
who were enrolled in 
a family study at 
Johns Hopkins 
Sibling-matched case-
control study; maternal 
parity 
Obstetric suboptimality score 
using Gilbert Optimality Scale 
and data from maternal 
interview or medical records. 
n=39 “autistic subjects” 
matched with n=39 
randomly matched sibling 
controls.  
Null   
N. Juul-Dam, 
2001 (58) 
74 children seen at a 
research center in 
California.  
Case-control study; none. 28 pre-, peri-, and neonatal 
risk factors obtained from 
parental interview and 
available obstetric and 
neonatal records. Including 
gestational diabetes (n=6), 
preeclampsia (n=8), and 
hyperbilirubinemia (n=22).  
Children with PDD (n=74) 
diagnosed between 2.5 to 4 
years old using DM-IV and 
ADI-R criteria, reevaluated 
at 5 yrs old where autism 
n=51 (10 excluded due to 
incomplete records) and 
PDD-NOS=13.  
Incidence was not 
statistically significantly 
higher at an alpha=0.05 
level for GDM or 
preeclampsia, was 
statistically significantly 
higher for 
hyperbilirubinemia.   
C.M. Hultman, 
2002 (43) 
Swedish Birth 
Register linked to the 
Swedish Inpatient 
Register from 1987-
1994.   
Population-based nested 
case-control study. 
Conducted analysis with 
a crude model and with a 
model that included all 
other variables in the 
analysis.  
Maternal, pregnancy, and 
infant characteristics, 
including complications 
during pregnancy, delivery 
and the neonatal period 
classified by ICD-8 and ICD-
9. Includes diabetes (n=4) and 
hypertensive diseases (n=24). 
Children discharged with a 
main diagnosis of infantile 
autism according to ICD-9 
from any hospital in Sweden 
before 10 years of age 
(n=408).  
Diabetes adjusted OR=1.2 
(95% CI 0.3-5.7) 
Hypertensive diseases 
adjusted OR=1.6 (95% CI 
0.9-2.9)  
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
H. Leonard, 
2006 (62) 
Linked datasets of 
236,964 children 
born in Western 
Australia between 
1983-1992.  
Population-based case-
control study; did not 
adjust for covariates.   
Preexisting medical conditions 
recorded on the midwives’ 
notification form for all births 
using ICD-9, including 
diabetes (n=6).  
Ascertained educational and 
disability services sources 
that link to the birth record 
using DSM-IV criteria, 
including children with mild 
to moderate ID (n=2462), 
severe or profound ID 
(n=212), and ASD with ID 
(n=191). Compared to 
children without ID. 
Diabetes (ASD with ID vs. 
no ID) OR=2.89 (95% CI 
1.28-6.51) 
Diabetes (Mild-moderate ID 
vs. no ID) OR=1.69 (95% 
CI 1.26-2.27) 
S. Buchmayer, 
2009 (52) 
Swedish Birth 
Register linked to the 
Hospital Discharge 
Register from 1987-
2002.   
Population-based case-
control study. Conducted 
analysis with a crude 
model and with a model 
that included all other 
variables in the analysis. 
Several maternal, pregnancy-
related, and neonatal factors 
collected from the Birth 
Register and Discharge 
Register including diabetes 
mellitus (n=18), gestational 
hypertension (n=21), 
preeclampsia (n=39).  
Children discharged with a 
main diagnosis of infantile 
autism according to ICD-
9/ICD-10 from any hospital 
in Sweden before 10 years of 
age (n=1,216). 
Diabetes crude OR=1.13 
(95% CI 0.67-1.89)/ 
adjusted OR=0.90 (95% CI 
0.49-1.67) 
Gestational hypertension 
crude OR=1.18 (95% CI 
0.73-1.92)/adjusted 
OR=1.04(95% CI 0.59-
1.81) 
Preeclampsia crude 
OR=1.41 (95% CI 0.98-
2.02)/adjusted OR=1.64 
(95% CI 1.08-2.49) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
I. Burstyn, 2010 
(68) 
Provincial delivery 
records for singleton 
live births in Alberta, 
Canada between 
1998-2004. 
Population-based birth 
cohort. Conducted 
analysis controlling for 
all maternal, obstetric, 
and neonatal risk factors 
that were collected.  
Maternal and obstetric risk 
factors extracted from the 
delivery records, including 
pre-pregnancy diabetes (n=16) 
and GDM (n=54), and 
preeclampsia (n=27). 
Children that were assigned 
an ICD-9 code for ASD by 
physician billing from at 
least one claim from any 
physician (n=1,138) 
Pre-pregnancy diabetes 
RR=1.65 (95% CI 1.01-
2.71) 
GDM RR=1.24 (95% CI 
0.94-1.65) 
Preeclampsia RR=1.49 
(95% CI 1.00-2.23) 
J. R. Mann, 
2010 (67) 
Women with 
singleton pregnancies 
in South Carolina 
Medicaid billing 
records from 1996-
2002 
Birth cohort from SC; 
controlling for maternal 
age, race, alcohol use, 
and educational 
attainment, year of birth, 
child’s sex. 
Maternal conditions/diseases 
during pregnancy 
(Preeclampsia n=52), lifestyle 
factors reported on the birth 
certificate, and child 
anomalies. 
ASD determined by all 
children receiving services 
from the SC Department of 
Disabilities and Special 
Needs or diagnosed with 
ICD-9 by at least two 
different providers (n=472) 
Preeclampsia/eclampsia 
OR=1.69 (1.26-2.28) 
L. Dodds, 2011 
(71) 
All live births in 
Nova Scotia Perinatal 
Database between 
1990-2002.  
Retrospective, 
longitudinal cohort study. 
Presented univariate 
results without 
controlling for 
confounding.  
Pre-pregnancy factors 
(diabetes n=7), prenatal 
factors, and pregnancy 
diseases/conditions (GDM 
n=32; PIH n=106), labor and 
delivery variables, and 
neonatal factors and neonatal 
diseases/conditions. OSS.  
Children that were assigned 
an ICD-9 code or ICD-10 
code for autism and any 
PDDs. Autism (n=924), no 
autism (n=128,809).  
Pre-pregnancy diabetes 
RR=1.98 (0.94-4.16) 
Gestational diabetes 
RR=1.29 (0.90-1.83) 
Pregnancy-induced 
hypertension (PIH) 
RR=1.24 (1.02-1.52) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
P. Krakowiak, 
2012 (12) 
CHARGE study, 
1,004 children 
between 24-60 
months in California 
recruited from 2003-
2010. 
Population-based case-
control study; maternal 
age, race/ethnicity, 
education level, delivery 
payer, calendar time. 
Metabolic conditions (MC), 
type 2 diabetes (n=4), GDM 
(n=44), history of 
hypertension (n=19), and 
obesity (n=111). Assessment 
by questionnaire and medical 
records (available for half). 
Children with a prior 
diagnosis of ASD were 
confirmed with the ADI-R 
and ADOS (n=517). SCQ 
administered to DD (n=172) 
and GP (n=315) children to 
evaluate for ASD.  
Diabetes OR=1.52 (95% CI 
0.82-2.83) 
Hypertension OR=2.84 
(95% CI 0.94-8.56) 
Obesity OR=1.67 (95% CI 
1.10-2.56) 
Any MC OR=1.61 (95% CI 
1.10-2.37) 
K. Lyall, 2012 
(60) 
Nurses Health Study 
II, 66,445 parous 
nurses in the U.S. 
enrolled from 1989-
2003 
Cohort Study; maternal 
age, race, marital status, 
income, spouse 
education, and parity. For 
GDM and HBP: history 
of miscarriage, prior 
abortion, pregnancy 
related HBP, other 
complications, etc.  
Obstetric suboptimality score 
and individual complications 
with first birth. Maternal 
report by questionnaire 
collected every two years, 
may have occurred with 
pregnancy other than index. 
GDM in first birth n=58, 
pregnancy-related HBP in first 
birth n=85. 
 
Maternal report in 2005 
asking women if they had a 
child with autism, Asperger 
syndrome, or “other autism 
spectrum disorder”, 
unknown if from first birth 
where exposure occurred; 
n=793 (1.2%). 
OSS of 4+ OR=2.96 (95% 
CI 1.74, 5.03) 
GDM OR=1.88 (95% CI 
1.15-3.07) 
Pregnancy-related HBP 
OR= 0.96 (95% CI 0.58-
1.59) 
S. G. Gregory, 
2013 (144) 
All recorded live 
births in North 
Carolina from the 
North Carolina 
Detailed Birth 
Record from 1990-98 
linked to educational 
data from 1997-98 
and 2007-08 school 
year.  
Controlled for induced or 
augmented birth, 
maternal age, maternal 
race/ethnicity, birth 
order, education, marital 
status, singleton birth, 
smoking, hypertension, 
diabetes.  
Induction or augmented birth 
was the main exposure, looked 
at contributing factors such 
maternal characteristics and 
maternal conditions during 
pregnancy (hypertension 
n=386; diabetes n=220).  
An autism diagnosis from 
public school educational 
records (n=5,648).  
Hypertension OR=0.95 
(95% CI 0.85-1.05)  
Diabetes OR=1.24 (95% CI 
1.08-1.42) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
A. T. Langridge, 
2013 (8) 
All live singleton 
births in WA 
between 1984-1999 
linked with data from 
population-based 
disability databases 
Adjusted for all maternal 
conditions, birth year, 
and sociodemographics. 
Maternal conditions and 
pregnancy outcomes 
(including diabetes and 
hypertension), labor and 
delivery complications, 
neonatal outcomes. No Ns 
avail. 
ASD (with ID and without 
ID) identified in state-wide 
disability database (N=752 
and 452, respectively) 
Diabetes OR= 1.03 (95% CI 
0.62-1.69) 
Hypertension OR= 1.34 
(95% CI 1.05-1.71) 
P. Polo-Kantola, 
2014 (164) 
Registry-based case-
control study from all 
singleton births in 
Finland from 1990-
2005 
Birth type, Apgar scores, 
neonatal treatment, 
smoking during 
pregnancy, parity, and 
maternal psychiatric 
history 
Maternal factors including 
high blood pressure (=56), 
birth factors, neonatal 
treatment 
Childhood autism obtained 
from hospital discharge 
registry (n=1036) 
High blood pressure 
OR=1.49 (95% 1.1-1.21) 
C. K. Walker, 
2015 (163)  
CHARGE study, 
1,004 children 
between 24-60 
months in California 
recruited from 2003-
2010. 
Population-based case-
control study; maternal 
educational level, 
pre-pregnancy obesity, 
and parity. 
Preeclampsia (n=32) and 
placental insufficiency.  
Children with a prior 
diagnosis of ASD were 
confirmed with the ADI-R 
and ADOS (n=517). SCQ 
administered to DD (n=194) 
and GP (n=350) children to 
evaluate for ASD.  
Preeclampsia OR=2.36 (95% 
CI 1.18, 4.68))  
A.H. Xiang, 
2015 (165)   
 
Retrospective 
longitudinal cohort 
study including 
322,323 singleton 
children born in 
1995-2009 at Kaiser 
Permanente 
Birth year, maternal age, 
parity, education, 
household income, 
race/ethnicity, 
history of comorbidity, 
and sex of the child.  
From birth record and medical 
record (GDM n=310, T2DM 
n=115). 
Clinical diagnosis of ASD in 
the medical record (n=3,388) 
T2DM OR= 1.21 (95% CI 
0.97-1.52) 
GDM OR= 1.04 (95% CI 
0.91-1.19) 
GDM <26 wks OR= 1.42 
(95% CI 1.15-1.74) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with 
outcome), ascertainment Measures of association 
N. Connolly, 
2016 (166) 
Medical records of 
children seen in 
behavioral clinic 
associated with 
Cincinnati Children’s 
Hospital, 2009- 2014 
Case-control study; 
maternal age, maternal 
race, year of birth, and 
BMI. 
Using ICD-9 codes and 
natural language processing, 
GDM (n=52) and preexisting 
diabetes (n=1), chronic 
hypertension (n=15), 
hypertension in pregnancy 
(n=29). 
Clinical diagnosis of ASD in 
the medical record from the 
behavioral clinic; non-ASD 
DD, and POP 
GDM OR=1.64 (95% CI 
1.22, 2.22) 
Obesity and GDM= 2.53 
(95% CI 1.72, 3.373) 
 
M. Li, 2016 
(167) 
Medical records, 
recruited at Boston 
Medical Center, 
1998-2014 
Prospective birth cohort; 
year or birth, sex, 
maternal age, parity, 
smoking, and preterm 
birth. 
Using ICD-9 codes, GDM 
(n=9), preexisting diabetes 
(n=10) 
Using ICD-9 codes, ASD 
(n=102) 
GDM HR=1.86 (95% CI 
0.92, 3.76) 
Preexisting diabetes 
HR=2.25 (95% CI 1.14, 
4.42) 
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F. The role of neonatal jaundice on neurodevelopment 
Both neonatal jaundice and hyperbilirubinemia have been associated with the 
development of ASD in the child. Jaundice, a yellow discoloration of the skin and the sclera of 
the eyes, occurs in most newborn infants usually as a result of increased bilirubin levels. During 
the neonatal period, fetal hemoglobin breaks down as it is replaced by adult hemoglobin, 
resulting in the release of bilirubin produced in the cells. Bilirubin travels through the 
bloodstream to be excreted by the liver, but this process may be prolonged due to an immature 
liver leading to an increase of bilirubin in the blood (168). Increased bilirubin levels may be seen 
more frequently with conditions characterized by increased hemolysis or other conditions 
compromising infant liver function. Jaundice may also be seen with breastfeeding due to factors 
in the breast milk that promote reabsorption of bilirubin after it is secreted into the intestinal 
tract, and can be more common when feeding times are irregular (168). Visual jaundice is seen in 
60% of term neonates and usually resolves within the first week of life (169, 170). However, if 
bound to albumin, bilirubin can cross the blood brain barrier where it may have toxic effects on 
the developing brain and may even cause death (Figure 2.2). Animal studies have shown 
bilirubin in regions of the basal ganglia, hippocampus, substantia nigra, and brainstem nuclei 
(171). High levels of bilirubin have been shown to cause mental retardation, cerebral palsy, and 
kernicterus in children (172).  Bilirubin can be measured directly from the blood or 
transcutaneously, neonates with high levels according to the Bhutani curve (Figure 2.4) may be 
treated with phototherapy or if not successful or in extreme cases, exchange transfusion (173).  
Recently, several studies have reported an association between high levels of bilirubin 
and the development of ASD in the child (52, 105, 174-176). Other studies did not find a 
statistically significant association (10, 177), but this may have been due to limitations such as 
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not accounting for confounders (10) and small sample sizes that make it difficult to detect 
associations at high levels of bilirubin exposure. These studies also have varying methods of 
collecting data and classifying jaundice, some using parental report, differing bilirubin cut-offs, 
or administrative codes. Many of these studies also fail to fully address the role of preterm birth 
and gestational age. For example, neonatal jaundice is more common in infants born preterm and 
infants may also be more susceptible to high levels of bilirubin at earlier gestational ages, which 
may affect the association with ASD(14). This study addresses these limitations and helps 
elucidate whether the association with perinatal complications and ASD is likely due to prenatal 
complications (maternal diabetes or hypertension) or subsequent neonatal complications 
(neonatal jaundice).  
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Figure 2.2. Biological mechanism for neonatal jaundice and hyperbilirubinemia in association with the development of ASD
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Table 2.2. Summary of studies that have looked at the association between neonatal jaundice or hyperbilirubinemia and ASD 
First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with outcome), 
ascertainment 
Measures of 
association 
L. A. Croen, 
2005 (177) 
Singleton term infants 
born between 1995 and 
1998 at a northern 
California Kaiser 
Permanente Hospital 
Nested case-control 
study; sex, birth 
facility, maternal age, 
maternal race/ethnicity, 
maternal education, 
gestational age 
Maximal neonatal bilirubin 
levels from medical records: 
15-19.9 mg/dL (n=27), 20-
24.9 mg/dL (n=6), ≥25 mg/dL 
(n=1) 
Children with an ICD-9 ASD 
diagnosis recorded in an 
outpatient database (n=338) 
15-19.9 mg/dL 
aOR=0.74 (0.48–1.15); 
20-24.9 mg/dL 
aOR=0.66 (0.27–1.59); 
≥25 mg/dL aOR=1.12 
(0.11–11.15) 
K. A. Jangaard, 
2008 (178) 
Infants with gestational 
age ≥35 weeks born in 
Nova Scotia, Canada 
from Jan 1 1994-Dec 
31 2000 in a Perinatal 
Database. 
Population-based 
cohort study; adjusted 
for fetal sex and parity.  
Infants identified as having 
hyperbilirubinemia, with 
moderate hyperbilirubinemia 
defined as TSB 230-<325 
μmol/L (n=19). 
ASD diagnosis from Canadian 
insurance database (n=187).  
Unadjusted 
RR=1.6(1.0–2.6) 
Adjusted RR=1.6(1.0–
2.5) 
R. D. Maimburg, 
2008 (175) 
Children born in 
Denmark from 1990-
1999. 
Population-based 
matched case-control 
study; adjusted for birth 
weight, gestational age, 
mother’s age. 
Medical record data from the 
prenatal and perinatal period, 
hyperbilirubinemia was 
defined if maximum bilirubin 
value in μmol/L exceeded 
10% of the infant’s weight in 
grams on the same day, if not 
available birth weight was 
used. A serum bilirubin test 
was only ordered if jaundice 
was visible.  
473 children <10 years old with 
a diagnosis of ASD in the 
Danish Psychiatric Central 
Register, and 473 controls from 
birth records.   
Serum bilirubin test: 
UOR=1.4(1.1–2.1); 
AOR=1.2(0.8–1.7) 
Hyperbilirubinemia- 
(by infant weight): 
UOR=5.6(2.2–14.5); 
AOR=3.7(1.3–10.5) 
(by birth weight): 
UOR=6.0(2.1–17.3); 
AOR=3.8(1.2–12.1) 
S. Buchmayer, 
2009 (52) 
Swedish Birth Register 
linked to the Hospital 
Discharge Register 
from 1987-2002.   
Population-based case-
control study; adjusted 
for all infant 
characteristics and 
neonatal complications 
of interest.  
Several maternal, pregnancy-
related, and neonatal factors 
collected from the Birth 
Register and Discharge 
Register including neonatal 
jaundice (n=74).  
Children discharged with a 
main diagnosis of infantile 
autism according to ICD-
9/ICD-10 from any hospital in 
Sweden before 10 years of age 
(n=1,216). 
Crude OR=1.32(1.01–
1.72) Adjusted 
OR=1.18(0.86–1.63) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with outcome), 
ascertainment 
Measures of 
association 
R. D. Maimburg, 
2010 (174) 
All children born in 
Denmark from Jan 1 
1994-Dec 31 2004. 
Population-based, 
follow-up study; 
smoking, irregular fetal 
presentation, Apgar 
score, parents’ age, 
mother’s citizenship, 
birth weight, congenital 
malformations. 
Birth and medical record data, 
jaundice exposure determined 
by ICD-10 
ICD-10 ASD diagnosis 
(n=532) and diagnosis of other 
disorders of psychological 
development  
Neonatal jaundice: 
Crude HR=1.84(1.26–
2.69); Adjusted 
HR=1.56(1.05–2.30) 
M. P. Mamidala, 
2013 (105) 
Obtained via simple 
random sampling of 
individuals from 8 
major Indian cities 
from Sept 2010-Dec 
2012. 
Case-control study; 
maternal age at 
delivery, sex, and birth 
year.  
Parent questionnaire regarding 
parental, prenatal, perinatal, 
and neonatal characteristics, 
including neonatal jaundice 
(n=64). 
481 ASD cases aged 2-10 
obtained from developmental 
centers and 481 typically 
developing controls obtained 
from schools.  
Neonatal Jaundice: 
Crude OR=3.58 (2.02–
6.35) 
Adjusted OR=2.89 
(1.58–5.28) 
G. Duan, 2014 
(176) 
Cases were treated in a 
hospital in Zhengzhou 
city, China from Feb 
2011-Feb 2013. 
Controls were healthy 
children from local 
kindergartens.   
Case-control study; 
parental age, paternal 
introversion, passive 
smoking, premature 
rupture of the fetal 
membrane, premature 
delivery, birth 
asphyxia. 
Neonatal jaundice (n=49) data 
collected from clinical data 
and parent report in cases and 
from parent report in controls.  
Pediatric autism cases (n=286) 
treated by a hospital in China, 
and 286 controls from schools.  
Neonatal jaundice crude 
RR=11.57 (1.86–34.72) 
Severe jaundice 
adjusted RR=21.81 
(12.22–35.54) 
W. Froehlich-
Santino, 2014 
(10) 
California Autism 
Twin Study (CATS), 
obtained from the 
California Department 
of Developmental 
Service from 1987-
2004. 
Population-based twin 
study; none.  
Parent questionnaire regarding 
specific complications of 
pregnancy, labor, and the 
neonatal period, including 
jaundice (n=59). 
ASD diagnosis verified by 
ADI-R and ADOS. N=388 
[194 twin pairs; 137 
individuals with ASD] from 
age 4-18 yo. One child in the 
twin pair must have ASD.   
Jaundice: OR=1.54 
(0.94–2.52) 
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First author, 
year 
Data source, 
population, and 
study period Design, confounders 
Exposures (n with ASD), 
ascertainment 
Outcome (n with outcome), 
ascertainment 
Measures of 
association 
Y. W. Wu, 2016 
(179) 
Infants born ≥ 35 
weeks in Northern 
California, seen at 
Kaiser Permanente 
from 1995-2011. 
Retrospective cohort 
study, TSB levels, 
treatment, maternal and 
paternal age, maternal 
and paternal education, 
maternal race/ethnicity, 
sex, gestational age, 
birth weight, apgar, 
year of birth.  
Total serum bilirubin levels in 
medical record, n=146 with 
TSB ≥20, n=848 with 
15<TSB<20, n=580 with 
phototherapy. 
ASD diagnosis either by ICD-9 
code, n=5,979 
TSB≥20 OR=1.09 
(95% CI 0.89, 1.35) 
15<TSB<20 OR=1.07 
(95 CI 0.98, 1.17) 
Phototherapy OR=1.10 
(95% CI 0.98, 1.24) 
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CHAPTER 3. METHODS 
A. Study design 
The Centers for Autism and Developmental Disabilities Research on Epidemiology 
(CADDRE) Network were established as regional centers of excellence for research on ASD and 
developmental disabilities in 2002. The CADDRE Network designed the Study to Explore Early 
Development (SEED) to better understand ASD phenotype and etiology. SEED is a multisite 
case-control study with population-based, multiple-source ascertainment of children with ASD 
and two comparison groups, children with developmental delays or disorders other than ASD 
(DD) and children sampled from the general population (POP). Case children (ASD) were those 
confirmed to have ASD based on DSM-IV criteria for autistic disorder, pervasive developmental 
disorder-not otherwise specified, and Asperger syndrome. Potential participants were recruited 
from a catchment area near the study sites in six states (California, Colorado, Georgia, Maryland, 
North Carolina, and Pennsylvania)(26).    
SEED was designed to be the largest multi-site epidemiological investigation of 
etiological and risk factors contributing to ASD. A clinical evaluation was conducted to confirm 
ASD diagnosis and assess all children’s neurodevelopment. SEED collected detailed data from 
maternal and child medical records, maternal interview, and birth certificates for the period 
covering the first maternal prenatal care visit through the child’s third birthday. Data collection 
was uniform across all study groups. A summary of data collection sources and questions used 
for this study are described in more detail below. More details on methods specific to each aim 
are presented in Chapter 4 and 5.  
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B. Study population 
SEED required eligible children to have been born in and reside in one of six study 
catchment areas between September 1, 2003 and August 31, 2006 and to be between the ages of 
30 and 68 months of age at the time of in-person assessment. SEED aimed to obtain a 
population-representative sample. The catchment areas were of similar population size in 
California, Colorado, Georgia, Maryland, North Carolina, and Pennsylvania. SEED also required 
the children to live with a knowledgeable caregiver who was at least 18 years of age and spoke 
English (or Spanish if participating in CO or CA)(26). For the purposes of this analysis, we also 
require that the caregiver be the biological mother because of the focus on prenatal data.  
Children in the ASD and DD groups were ascertained through multiple agencies that 
evaluate or serve children with developmental challenges, even if they did not already have a 
specific diagnosis of ASD or other developmental disability. Recruitment targeted agencies 
focused on early intervention, special education, and related service programs for toddlers and 
young children, as well as hospitals, clinics, and individual providers. Parents also might have 
contacted the study directly and the child enrolled if eligible. This “broad diagnostic net” for 
ascertainment ensures that previously diagnosed and undiagnosed ASD children were identified 
(26). SEED’s recruitment procedures across multiple agencies and multiple sites ensured sample 
diversity that should be more generalizable to the broad US population than single clinic-based 
studies.  
State birth records were randomly sampled to identify children from the general 
population to invite for participation. POP children were required to be born in the specified date 
range, whose mothers were residing in the study catchment area at time of delivery, and were 
still alive at time of invitation to participate in the study. Families in all three recruitment groups 
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were invited to participate in the study via mail and, if interested, received a follow-up call. 
During this call, the Social Communication Questionnaire (SCQ) (180) was administered to the 
child’s primary caregiver to screen the child for ASD. SEED ascertainment and evaluation 
procedures are described in more detail below and in Figure 3.1. This analysis is composed of 
children enrolled in SEED that have data available from either the caregiver interview or medical 
records on the exposure of interest and met criteria for one of the three outcome groups discussed 
in more detail below.  
C. Outcome assessment  
ASD ascertainment 
During the initial recruitment call, a positive screen was defined as an SCQ ≥11. This 
lower cut-point was used to increase the sensitivity of the screener because of children’s young 
age (26). Children who screened positive or had a previous diagnosis of ASD were placed in an 
ASD workflow and received a standardized in-clinic assessment by trained research-reliable 
clinicians. ASD was confirmed by both the Autism Diagnostic Observation Schedule (ADOS) 
(181, 182) and the Autism Diagnostic Interview-Revised (ADI-R) (183) as meeting standard 
criteria for both instruments, or relaxed criteria for the ADI-R if criteria for the ADOS is met as 
described in Table 3.1. Children in the ASD workflow that were untestable or refused to take the 
ADOS/ADI-R during clinical evaluation were placed in a separate “Possible ASD” group; 
children in this group are excluded from this study.   
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Figure 3.1. SEED recruitment and final classification of participants.  
The general development of all children was assessed in the clinic using the Mullen 
Scales of Early Learning (184). All parents also completed several instruments to characterize 
their child’s development including the Child Behavior Checklist (185) and the Social 
Responsiveness Scale (186). All children in the ASD workflow, and those in DD or POP 
workflow with an Early Learning Composite score of ≤78 on the Mullen Scales, also completed 
the Vineland Adaptive Behavior Scales (187). If the clinician suspected that a child in the DD or 
POP had possible ASD at the time of evaluation, the child was moved to the ASD workflow and 
the ADOS/ADI-R was administered.  
All SEED clinicians have advanced degrees in developmental pediatrics, developmental 
psychology, clinical psychology and related fields and experience with the assessment and 
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diagnosis of children with ASD (188). Clinicians who administered the ADI-R and ADOS 
participated in pre-data collection exercises to establish reliability, at least quarterly exercises to 
maintain reliability, and at least yearly exercises to verify administration fidelity (188). 
Table 3.1. Instruments administered in SEED and criteria for ASD classification 
Instrument  Domains  Criteria  
Autism Diagnostic 
Observation Scale-2 
(ADOS) (181, 182) 
Social effect  
Restricted interests and 
repetitive behaviors (RRB) 
Module 1 with no words=11  
Module 1 with some words=8 
Module 2 less than 59 months=7  
Module 2 more than 59 months=8 
Module 3=7 
Autism Diagnostic 
Interview- Revised (ADI-
R) (183) 
 
Social  
Communication  
RRB 
Standard: Social=10; Communication=8 for verbal 
children or 7 for nonverbal children; RRB=3 
Relaxed (when child meets the ADOS criteria but 
not standard ADI-R) Social=10 and 
Communication=6 for verbal children or 5 for 
nonverbal children; Communication=8 for verbal 
children or 7 for nonverbal children and RRB=8; 
Social=10 and RRB=2 
DD and POP comparison group ascertainment 
Two different comparison groups were included in SEED: 1) children with 
developmental delays or disorders other than ASD (DD), and 2) children sampled from the 
general population (POP). Comparisons between the ASD and POP group identify risk factors in 
children with ASD relative to children from the general population. Comparisons between the 
ASD and DD group can identify unique risk factors to ASD independent of risks common to 
other developmental disorders.  
Children with an SCQ <11 were grouped according to their recruitment source, with 
those entering through the Broad Diagnostic Network placed in the DD workflow and those 
sampled from vital records placed in the POP workflow. If the clinician suspected that a child in 
the DD or POP workflow had possible ASD at the time of in-person evaluation, the child was 
moved to the ASD workflow and the ADOS/ADI-R was administered. Otherwise, they were 
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classified as Final DD or Final POP. Children in the ASD workflow that were ADOS and ADI-R 
negative or had a discrepancy in their ADOS/ADI-R that could not be resolved were classified as 
Final DD if recruited from the Broad Diagnostic Network, or as Final POP if recruited from vital 
records.  
The DD group includes children that may have a previous ASD diagnosis or with 
observed or reported ASD characteristics. Sub-classifications were created in the DD group to 
designate children that fall into these categories. For the purposes of this analysis, these children 
are excluded in order to have a DD comparison group that is distinct from ASD and more 
representative of other developmental disorders. While children with these characteristics may 
also be found in the POP group, all POP children are included to maintain its representativeness 
of a true population control group.   
D. Exposure assessment 
Exposure assessment included data from available sources: medical record (including 
hospital stays and clinic visits) and maternal report (from interview and health history forms). 
This is described in more detail in more detail below. 
Medical records  
At enrollment, all participants were mailed medical records release forms. Once the 
signed release forms were obtained, hospital and clinic medical records were obtained from the 
prenatal, labor/delivery, neonatal, and pediatric periods, from which data was abstracted into four 
corresponding data collection forms by trained data abstractors. Quality control steps were 
implemented including training exercises for data abstraction, and testing initial and ongoing 
quality control standards for all data collected from medical records. Data from the medical 
records were abstracted to multiple forms arranged by topic such as Prenatal Care, Labor and 
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Delivery, Neonatal/Birth Hospital, and Pediatric. Questions used for this analysis from these 
forms are described below in Tables 3.2, 3.4, and 3.5 below. 
Caregiver interview (CGI) 
Following enrollment, the caregiver was interviewed via telephone by a trained 
interviewer with computer assistance. If the mother was the caregiver being interviewed, 
questions were asked regarding sociodemographic information, maternal health history and 
medical conditions, and regarding the pregnancy with the index child including complications, 
and conditions or complications during pregnancy, delivery and the early postnatal period. 
Questions from the CGI that are used for this analysis are included below in Tables 3.2, 3.4, and 
3.5 below. 
Autoimmune disease survey  
Following the caregiver interview, a questionnaire packet was mailed to the caregiver. 
Two of the forms included were a family autoimmune disease history survey, in which the 
mother would indicate whether she has ever had an autoimmune condition and her age of onset. 
Gestational diabetes and diabetes (either requiring insulin or with no insulin use) were included 
in this form. Data used for this analysis from this questionnaire are described in Tables 3.2, 3.4, 
and 3.5 below.  
Diabetes in pregnancy 
Mothers with diabetes in pregnancy include those with a diagnosis of gestational diabetes 
(GDM), Type I diabetes (T1DM), Type II diabetes (T2DM), or diabetes-not otherwise specified 
(diabetes- NOS). Any report of diabetes in the caregiver interview, the autoimmune disease 
survey, or the prenatal medical record, is used to classify diabetes. In those with a date of 
diagnosis available, a new diagnosis of diabetes-NOS before the 20th week of pregnancy was 
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classified as T2DM. A new diagnosis of diabetes-NOS at or beyond 20 weeks of gestation (in 
those with a date of diagnosis available) is classified as GDM. In addition, results from an oral 
glucose tolerance test (OGTT) are used when available to identify women with GDM (see 
below). Because it is often difficult to distinguish undiagnosed T2DM and GDM, we have a 
broad exposure category of ‘Any diabetes’ that includes GDM, T2DM, T1DM, and diabetes-
NOS. Mothers previously diagnosed with diabetes with an active diagnosis in their prenatal 
medical record are also included.  
 Table 3.2 describes the sources of data and specific information collected regarding 
maternal diabetes. From these sources we determined if the mother had diabetes during or before 
her pregnancy, the type of diabetes diagnosed, results from glucose tolerance tests during the 
pregnancy, and if she was taking medications for the diabetes.  
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Table 3.2. Sources of data in SEED pertaining to diabetes in pregnancy  
Data Source Condition 
Section 
Variable Name Question  
Possible 
Responses 
Maternal 
Interview  
 
 
 
Diabetes, 
not 
specified 
CGIE2727_MedCondition 
   MI_E27_DIB 
 
Did you take any medications or 
receive any treatment for diabetes 
during the time period of 3 
months before pregnancy and 
index child’s date of birth? 
0 = 'No' 
1 = 'Yes' 
Missing 
GDM CGIF0101_Intro 
   MI_F1_GDB 
Did you have gestational diabetes 
during your pregnancy with index 
child? 
0 = 'No' 
1 = 'Yes' 
Missing 
Autoimmune 
Disease 
Survey 
 
GDM 
 
AID_Condition_09_16 
   AI_GDI_MX 
Gestational diabetes in the 
mother? 
0 = 'No' 
1 = 'Yes' 
   AI_GDIAGE_MX Age of onset of GDM 
Numeric (years) 
Restricted to 1 
yr before age at 
birth  
Diabetes 
requiring 
insulin 
 
AID_Condition_09_16 
   AI_DBI_MX 
Diabetes requiring insulin in the 
mother? 
0 = 'No' 
1 = 'Yes' 
   AI_DBIAGE_MX Age of onset of diabetes 
Numeric (years) 
Restricted to 1 
yr before age at 
birth 
Diabetes 
with no 
insulin 
 
AID_Condition_09_16 
   AI_DBN_MX 
Diabetes with no insulin use? 0 = 'No’ 
1 = 'Yes' 
   AI_DBNAGE_MX Age of onset of diabetes 
Numeric (years) 
Restricted to 1 
yr before age at 
birth 
Prenatal 
Medical 
Record 
 
 
 
GDM 
 
MRA_PRE_C_PregHistoryDet
ail1 
   PR_C10L9_GEST 
Complications with mother– 
GDM? 
 
0 = 'No' 
1 = 'Yes' 
   PR_C_GEST Indicate whether GDM occurred 
in index pregnancy or one or 
more past pregnancies 
1='Index' 
2='Past' 
3=’Both’ 
GDM  
Diabetes, all 
types;  
MRA_PRE_E_BloodType 
   PR_E9A_FBS 
   PR_E9A_OTHSP 
Glucose tolerance tests- FBS  
 
 
1 = 'NL (1)' 
2 = 'ABNL (2)' 
Missing 
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GDM was also classified based on results from an oral glucose tolerance test (OGTT). 
The OGTT is typically performed during 24-28 weeks of gestation, but may be used as early as 
the 20th week to diagnose gestational diabetes. The results from the OGTT are recorded as 
“Normal” or “Abnormal” for each hour that blood glucose was measured. Two abnormal 
measurements are needed to classify the mother as having gestational diabetes. In the instances 
where “Normal” or “Abnormal” are not specified in the medical record, the numerical value 
under “Other” for the OGTT are used if available. To classify a woman as having GDM, these 
results from the OGTT must meet criteria for guidelines published by Carpenter and Coustan 
(189) (see Table 3.3), that are recommended by the American Diabetes Association (ADA) (190) 
and the American Congress of Obstetricians and Gynecologists (ACOG) (191). In some clinical 
practices, a glucose screen may be conducted to identify women at high risk for diabetes who 
should be followed-up with an OGTT. However, glucose screens are not used for diagnosis of 
GDM, the standard is the use of OGTT.  
There are two types of OGTT, one uses a 100-g oral glucose load and measures blood 
glucose at fasting baseline and again over three hours, and the other uses a 75-g oral glucose load  
GDM 
 
 
   PR_E9C_1HOUR 
   PR_E9C_OTHSP 
Glucose tolerance tests- 1 hour  
 
1 = 'NL (1)' 
2 = 'ABNL (2)' 
Missing 
30 = 'Type I 
Diabetes' 
33 = ‘GDM’ 
32 = 'Diabetes- 
NOS' 
31 = 'Type II 
Diabetes 
   PR_E9D_2HOUR 
   PR_E9D_OTHSP 
Glucose tolerance tests- 2 hour  
 
   PR_E9E_3HOUR 
   PR_E9E_OTHSP 
Glucose tolerance tests- 3 hour  
 
MRA_PRE_M_Med Cond 
   PR_MA_COND 
Medical conditions during 
pregnancy and date or age at 
diagnosis  
Diabetes, 
not 
specified 
MRA_PRE_Q_All Meds 
   PR_QB_CODE 
Medications taken during index 
pregnancy  
2 = 
'Antidiabetes 
(10)' 
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and measures blood glucose at fasting baseline and again over two hours. At least two of the 
glucose measurements in Table 3.3 must be met or exceeded in order to fulfill criteria for GDM. 
Mothers with a previous history of diabetes that is 
not active during the pregnancy with the index 
child were not excluded from the analysis and 
were classified as unexposed. 
Hypertension in pregnancy   
A mother was classified as having hypertension if she reported it during the caregiver 
interview or if there was a diagnosis in the medical record of a hypertensive disorder during 
pregnancy such as pregnancy-induced hypertension (PIH), preeclampsia, eclampsia, or 
hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. Serial blood pressure 
measurements recorded during clinic and hospital visits were abstracted from the medical record 
when available. Blood pressure measurements were also used to identify women with PIH (see 
below).  
Table 3.4 describes the data collected regarding maternal hypertension during pregnancy. 
We used medical record and maternal report to determine the onset of hypertension before or 
during pregnancy, the type of hypertension diagnosed, and if the mother used anti-hypertensive 
medications. 
In addition to the broader category of ‘Any Hypertension,’ mothers were classified into 
three subclassifications of hypertensive disorders: 1) preexisting or chronic hypertension, 2) 
pregnancy-induced hypertension, or 3) preeclampsia, eclampsia, or HELLP. The first and last 
categories were allowed to overlap as mothers with chronic hypertension before pregnancy can 
develop preeclampsia, eclampsia, or HELLP. However, there was no overlap with PIH and the 
 100-g oral glucose 
load 
75-g oral 
glucose load 
mg/dL mmol/l mg/dL mmol/l 
Fasting 95 5.3 95 5.3 
1-hour 180 10.0 180 10.0 
2-hour 155 8.6 155 8.6 
3-hour* 140 7.8  
Table 3.3. Criteria for diagnosis of GDM 
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other subclassifications.  Mothers with a previous history of hypertension that was not active 
during the pregnancy with the index child were not excluded and thus classified as unexposed.  
Table 3.4. Sources of data in SEED pertaining to hypertension in pregnancy  
Data 
Source 
Conditions  Section 
Variable Name 
Question Responses 
Maternal 
Interview 
 
 
 
High blood 
pressure, not 
specified 
CGIE2727_Med Condition 
  MI_E27_HBP 
 
Did you take any medications or 
receive any treatment for high 
blood pressure? 
0 = 'No' 
1 = 'Yes' 
Missing 
Eclampsia CGIF0101_Intro 
MI_F1_ECLM 
Did you have eclampsia during 
your pregnancy?  
0 = 'No' 
1 = 'Yes' 
Missing 
PIH/Preeclampsia  MI_F1_HTN 
 
Did you have pregnancy-induced 
hypertension or preeclampsia 
during your pregnancy? 
0 = 'No' 
1 = 'Yes' 
Missing 
HELLP syndrome  MI_F1_HELP 
 
Did you have HELLP syndrome 
during your pregnancy? 
0 = 'No' 
1 = 'Yes' 
Missing 
Maternal 
Medical 
History 
Form 
 
High blood 
pressure, not 
specified 
MMH_CondInfo2 
 MM_21_HBPX 
 
Did you have the condition 
during pregnancy with the study 
child? – High blood pressure 
0=’No’ 
1=’Yes’ 
Missing 
MM_43_OTH Other? Specify.  Write-in string 
Prenatal 
Medical 
Record 
 
Eclampsia, HELLP 
syndrome, PIH/ 
Preeclampsia/ 
Gestational 
hypertension 
 
MRA_PRE_C_PregHistory
Detail1 
PR_C10L7_ECL 
 
PR_C10L10_HELLP 
 
PR_C10L19_PIH 
Complications with mother – 
Eclampsia?  
0 = 'No' 
1 = 'Yes' 
Complications with mother – 
HELLP  
0 = 'No' 
1 = 'Yes' 
Complications with mother – 
pregnancy induced hypertension, 
preeclampsia, gestational 
hypertension  
0 = 'No' 
1 = 'Yes' 
MRA_PRE_C_Comp 
PR_C_ECL 
Indicate whether GDM occurred 
in index pregnancy or one or 
more past pregnancies 
1='Index' 
2='Past' 
3=’Both’ 
 
PR_C_HELLPL 
PR_C_PIH 
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Gestational 
hypertension 
 
MRA_PRE_D_MaternMe
asDetail1 
PR_D4H_SBP 
PR_D4I_DBP 
D4. Blood pressure – Systolic and 
Diastolic 
2 or more 
elevated 
measurements 
Eclampsia, 
HELLP 
syndrome, 
Preexisting 
hypertension,  
PIH/ preeclampsia 
MRA_PRE_M_Med Cond 
   PR_MA_COND 
Medical conditions during 
pregnancy and time period  
36= Eclampsia 
48= HELLP  
55= Pre-
existing 
Hypertension 
79= PIH/ 
Preeclampsia 
Pregnancy-induced hypertension is be defined according to ACOG guidelines as having a 
systolic blood pressure ≥140 mmHG and/or a diastolic blood pressure ≥90 mmHg on at least two 
occasions that was 1) at least four hours apart (in order to minimize error) 2) taken after the 20th 
week of pregnancy, and 3) meeting criteria for being previously normotensive with no signs of 
proteinuria (192). Mothers who are diagnosed with preeclampsia (with or without signs of 
proteinuria or the development of end-organ dysfunction) are defined as having hypertension as 
the above for PIH, plus must have evidence of 1) proteinuria or abnormal protein levels in the 
urine, or 2) taking Magnesium for prevention of seizures.  
Neonatal jaundice and hyperbilirubinemia 
Unlike hypertension and diabetes, a diagnosis of neonatal jaundice may not require a 
formal diagnostic test even though it is caused by elevated levels of bilirubin in the blood.  
Jaundice is often identified by the yellowing appearance of the skin and sclera of the eyes. Some 
methods used to diagnose jaundice, such as blanching the skin with pressure to reveal underlying 
skin tone and using an Ingram icterometer (pressing and matching one of 5 shades of transparent 
plastic against an infant’s skin), can be subjective and not accurately representative of bilirubin 
levels in the blood. However, clinicians often rely on these methods because of convenience and 
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quick interpretation, particularly when severe jaundice or prolonged hyperbilirubinemia is not 
suspected. Directly measuring bilirubin in the blood is ideal, but is highly dependent on the 
timing of the bilirubin measurement.  If the blood test is not done at the time jaundice was 
visible, it may not be indicative of the highest levels of bilirubin the infant was exposed to.  
 For this analysis, neonatal jaundice is defined as 1) maternal report of neonatal jaundice 
or treatment for neonatal jaundice in the CGI, and/or 2) diagnosis of jaundice or record of 
treatment for jaundice within the first 28 days of life in the neonatal or pediatric medical record. 
Treatment for neonatal jaundice includes phototherapy (bili light or blanket) or exchange 
transfusion in severe cases. Bilirubin levels are also used to identify jaundice and to identify 
infants who were at high risk for hyperbilirubinemia during the neonatal period (see below).  
Table 3.5 describes the sources of data that were used to identify children who had 
jaundice or high bilirubin levels. Variables for jaundice and bilirubin levels were created based 
on the questions in Table 3.5 as described below.   
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Table 3.5. Sources of data in SEED pertaining to neonatal jaundice  
Data 
Source 
Conditions   Question 
Maternal 
Interview 
 
Jaundice 
 
CGIF0816_ObstCompDeliv 
MI_F15_JAUN 
F15. During or after delivery of you 
child, did any of the following occur 
to your child? (09= Jaundice) 
Jaundice treatment MI_F16_PHOTO F16. Did your child receive 
phototherapy or bili lights, bili 
blanket, or special lights? 
Neonatal 
Medical 
Record 
 
Hyperbilirubinemia MRA_Neo_G_Bilirubin 
NE_GB1_TOTAL 
 
Bilirubin levels (see Table 3.2 for 
cut-offs) 
Hyperbilirubinemia 
treatment 
 
NE_GC1_IV 
NE_GC2_PHOTO 
NE_GC3_EXCH 
Treatment of hyperbilirubinemia 
(including phototherapy, exchange, 
IV) 
Hyperbilirubinemia/ 
jaundice 
MRA_Neo_J_MedHistory 
NE_JA_MEDHX 
Medical history of 
(145=hyperbilirubinemia/jaundice) 
Hyperbilirubinemia MRA_NEO_Q_Blood_Product 
NE_Q2C_HYPBIL 
Q2c. Blood product transfusion for 
hyperbilirubinemia 
Pediatric 
Medical 
Record 
Hyperbilirubinemia/ 
jaundice 
MRA_Peds_C_MedHist 
PD_CA_CODE 
J1. Medical history 
(145=hyperbilirubinemia/jaundice) 
 In addition to the broader category of ‘Any neonatal jaundice,’ infants were classified 
into three subclassifications of neonatal jaundice defined as 1) Definite, if treatment for neonatal 
jaundice was reported in either the medical record or maternal interview, 2) Probable, if a 
diagnosis of jaundice was available in the medical record, but treatment was not reported, or 3) 
Possible, if neonatal jaundice was only reported through maternal interview.  
Hyperbilirubinemia, defined as a total serum bilirubin measurement above the 95th 
percentile, was classified according to the Bhutani nomogram (Figure 3.2). The Bhutani 
nomogram is used among infants born ≥35 weeks gestation and evaluates the measurement 
relative to the age of the infant (in 12-hour increments). The nomogram defines 95th percentile, 
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75th percentile, and 40th percentile tracks for bilirubin measurements and designates the zones 
above as high-risk, high-intermediate risk, and low-intermediate risk (respectively) for any 
significant hyperbilirubinemia (subsequent measurement in the 95th percentile).(173, 193) We 
created mutually exclusive subclassifications based on the Bhutani recommended cut-offs (Table 
3.6) and defined the referent group as infants with no bilirubin measurement or with bilirubin 
measurements below the 40th percentile, and no neonatal jaundice indicated in the medical record 
or maternal interview. A variable encompassing any bilirubin level above the 40th percentile was 
also created to characterize infants with ‘Any elevated bilirubin measurement.’  
 
 
Figure 3.2. Bhutani curve for hyperbilirubinemia cut-offs (193) 
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Table 3.6. Bilirubin measurement cut-offs for hyperbilirubinemia and visible jaundice for infants 
35 weeks gestational age (193) 
Time since 
birth (hours) 
Bilirubin Measurement Levels (mg/dL) 
95th Percentile 
Hyperbilirubinemia 
75th Percentile 
High-Intermediate  
40th Percentile 
Low-Intermediate  
0-12 6.7 4.5 3.75 
>12-16 6.5 5.25 4.25 
>16-20 7.25 5.8 4.75 
>20-24 7.75 6.5 5 
>24-28 8.9 7 5.5 
>28-32 10 8 6.3 
>32-36 11 9 7.1 
>36-40 12.1 9.9 7.8 
>40-44 12.5 10.1 8.1 
>44-48 13.1 10.8 8.7 
>48-52 13.9 11.25 8.9 
>52-56 14.5 12 9.2 
>56-60 15.1 12.5 9.7 
>60-64 15.3 12.9 10.1 
>64-68 15.7 13.1 10.7 
>68-72 16 13.4 11.1 
>72-76 16.1 13.8 11.3 
>76-80 16.5 14.2 11.45 
>80-84 16.7 14.6 11.6 
>84-96 17.25 15.1 12.3 
>96 17.25 15.5 13.2 
Concordance between data sources  
Preliminary analyses were conducted to evaluate the concordance between data from 
medical records and maternal report. Agreement was substantial for data regarding maternal 
diabetes (97% agreement, Cohen’s Kappa=0.80) and maternal hypertension (90% agreement, 
Cohen’s Kappa=0.61) during pregnancy, but fair for neonatal jaundice (69% agreement, Cohen’s 
 44 
Kappa=0.35) (194). We believe this may be due to mild jaundice not receiving a formal 
diagnosis and delayed timing of the bilirubin laboratory test. Based on this, data from either the 
medical record or maternal report will be used to define the exposures for Specific Aim 1. 
However, for Specific Aim 2, two separate analyses will be conducted: 1) using neonatal 
jaundice as the exposure, as reported by maternal interview or a diagnosis in the medical record, 
or a report of treatment for jaundice in either data source, and 2) using bilirubin measurements 
abstracted form the medical record, and classified into percentiles using the Bhutani nomogram. 
E. Covariate assessment  
A thorough literature search was conducted to identify covariates that may be potential 
confounders in the association of these exposures with ASD or broader developmental delays. 
Table 3.7 contains all of the potential confounders identified and information on the data source 
for these variables in SEED and contains links to references that have established an association 
with maternal diabetes (DM), maternal hypertension (HTN), or jaundice (JN) and ASD.  
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Table 3.7. Summary of covariates associated with perinatal exposures and with ASD in the 
child.  
Covariate Data Source Association with exposure(s) Association with ASD 
Pre-pregnancy BMI Prenatal medical 
record 
DM: (19, 195-199) 
HTN: (195, 200-204) 
(12, 65, 71) 
 
Maternal race/ethnicity Maternal interview DM: (205-208) 
HTN: (202, 204, 209) 
JN: (210, 211) 
(59, 212) 
Maternal education 
(or other SES proxy) 
Maternal interview DM: (213) 
HTN: (214) 
JN: (211, 215) 
May also be associated with 
maternal report 
(59, 215, 216) 
 
Maternal age at delivery Prenatal medical 
record 
DM: (207, 208, 217) 
HTN: (202, 203) 
JN: (211, 218) 
(59, 219, 220) 
Parity Maternal interview HTN: (202, 203) 
JN: (175, 211) 
May also be associated with 
maternal report. 
(13, 61, 175, 221, 222) 
Plurality Maternal interview HTN: (203, 223) (224-226) 
Maternal smoking Maternal interview DM: (198, 208, 227-229) 
HTN: (204) 
JN: (211) 
(43, 230, 231) 
Infant sex Neonatal medical 
record 
JN: (211, 218, 232) (233) 
Infant race/ethnicity Maternal interview JN: (211, 218, 232) (59, 212) 
Pre-term birth Neonatal medical 
record 
JN: (211, 218, 234) (8, 235-237) 
DB: Diabetes; HTN: Hypertension; JN: Jaundice 
F. Statistical analysis 
We hypothesized that prenatal and neonatal complications would be associated with an 
increased risk of ASD in the child. We used multivariable logistic regression models to obtain 
odds ratios (OR) for having ASD vs. POP given these exposures. We evaluated the specificity of 
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this association by comparing these effect estimates to the ORs for DD vs. POP. We used the 
Mullen Scales of Early Learning Composite Standard Score of identify children with ASD and 
intellectual disability (ID; score <70) or ASD without ID (score ≥70) and further evaluated for 
differences between ASD with ID compared to ASD without ID. 
For each aim, a Directed Acyclic Graph (DAG) was used to identify potential 
confounders based on their associations with the exposure and the outcome in the literature 
(238). We evaluated the association of the confounders identified through the DAG with the 
exposure and outcome. Those that showed no association were excluded to obtain a more 
parsimonious model. Confounders were included as covariates in multivariable logistic 
regression model for each aim. Logistic regression models were used to evaluate the association 
between ‘Any diabetes,’ ‘Any hypertension,’ and ‘Any neonatal jaundice.’ Separate models were 
created for sub-classifications of diabetes (GDM and preexisting diabetes), hypertension 
(preexisting hypertension, PIH, and preeclampsia, eclampsia, and HELLP), and neonatal 
jaundice (definite, probable, and possible).    
Previous studies have shown interaction between BMI and maternal diabetes and 
hypertension, and between gestational age and neonatal jaundice. We assessed for interaction by 
including an interaction variable in our model and obtaining a p-value for the interaction term. 
An alpha level α=0.20 was set a priori for significance of the interaction term. We also obtained 
stratum-specific estimates and evaluated for any departure from homogeneity and tested the 
assumption of a multiplicative model.   
Specific Aim 1a 
Factors that have been associated with the exposure of maternal diabetes in pregnancy 
and the outcome of ASD are shown in the DAG in Figure 3.3. These include: maternal age at 
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conception, maternal race/ethnicity, maternal education (as a proxy for socioeconomic status 
[SES]), maternal smoking (any smoking 3 months before conception or during pregnancy), and 
study site. Maternal hypertension and BMI are variables that depending on the onset of diabetes 
(which can be difficult to determine) may be confounders, mediators, or moderators. Thus, these 
variables were added separately into the model and we assessed for interaction between these 
variables and maternal diabetes. Data on all covariates was obtained from maternal interview, the 
prenatal medical record, or birth certificate data if the other data sources are missing. 
 
 
Figure 3.3. Directed Acyclic Graph (DAG) of the relationship between maternal diabetes in 
pregnancy in Specific Aim 1a and the outcome of ASD or DD 
 The exposure group of “any maternal diabetes during pregnancy” is broad and 
heterogeneous. It is possible that the association with ASD is stronger in mothers with 
preexisting diabetes or GDM. For this reason, we also present results for these two 
subclassifications as defined above.  
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Specific Aim 1b 
Factors that have been associated with the exposure of maternal hypertension in 
pregnancy and the outcome of ASD are shown in the DAG in Figure 3.4. These include: 
maternal age at conception, maternal race/ethnicity, maternal education (as a proxy for SES), 
maternal smoking (any smoking 3 months before conception or during pregnancy), plurality, and 
parity. As before, maternal diabetes and BMI are variables that depending on the onset of 
hypertension (which can be difficult to determine) may be confounders, mediators, or 
moderators. Thus, these variables were added separately into the model and we assessed for 
interaction between these variables and maternal hypertension. Data on all covariates was 
obtained from maternal interview, the prenatal medical record, or birth certificate data if the 
other data sources are missing. 
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Figure 3.4. Directed Acyclic Graph (DAG) of the relationship between maternal hypertension in 
pregnancy in Specific Aim 1b and the outcome of ASD or DD 
The exposure group of “any maternal hypertension during pregnancy” is broad and 
heterogeneous. It is possible that the association with ASD is stronger in mothers with 
preexisting hypertension, PIH, or more severe hypertensive disorders such as preeclampsia, 
eclampsia and HELLP. For this reason, we also present results for these three subclassifications 
as defined above.  
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Specific Aim 2  
Factors that have been associated with the exposure of neonatal jaundice and the outcome 
of ASD are shown in the DAG in Figure 3.5. These include: maternal age at conception, 
maternal education, maternal diabetes during pregnancy, parity, plurality, infant race/ethnicity, 
infant sex, and gestational age at birth. These covariates were obtained from maternal interview, 
the prenatal or neonatal medical record, or birth certificate data if the other data sources are 
missing. 
 
 
Figure 3.5. Directed Acyclic Graph (DAG) of the relationship between neonatal jaundice and 
hyperbilirubinemia in pregnancy in Specific Aim 2 and the outcome of ASD or DD 
 While the exposure variable for neonatal jaundice was inclusive of all reports of jaundice 
in the CGI and medical record, we also evaluated the association between subclassifications of 
neonatal jaundice and ASD/DD. As described above, these include 1) Definite jaundice requiring 
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treatment, 2) Probable jaundice with a diagnosis in the medical record, or 3) Possible jaundice 
only reported in the CGI. Categories for elevated bilirubin levels according to cut-offs from the 
Bhutani nomogram were also evaluated in association with ASD/DD.  
The role of preterm birth in specific aim 2 
Neonatal jaundice and ASD are more common in the preterm infant. For this reason, we 
carefully considered the role of gestational age in our analysis. First, we assessed for interaction 
using the <35 weeks gestation, 35-37 weeks gestation, and ≥38 weeks gestation categories used 
by the American Academy of Pediatrics for the treatment of neonatal jaundice (173). We 
obtained stratum-specific estimates for jaundice and ASD/DD by these gestational age strata. 
Because the preterm brain and liver function are less developed, we hypothesized that a stronger 
association would be observed among infants born <38 weeks gestation.  
Sensitivity analysis  
Potential misclassification of the exposure 
It is possible that the exposure is misclassified due to poor maternal recall or missing 
medical records. Many of the variables abstracted from the medical records in SEED did not 
require the abstractor to enter ‘No’ for the condition if no diagnosis was found, only a ‘Yes’ if it 
was. This may lead to misclassification if the participant is classified as unexposed due to a 
‘Yes’ not being entered. Mothers also reported conditions during pregnancy on the CGI up to 68 
months after giving birth. For each exposure variable, there were mothers or infants that were 
discordant based on data from maternal report and medical record. These discordant pairs may 
be more likely to be misclassified. While we assume that this misclassification is non-
differential, it may still have an effect on our results. To evaluate this, we created a ‘Confirmed’ 
variable for diabetes and hypertension, which required a diagnosis in both the medical record and 
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CGI. For jaundice, we created subclassifications of 1) Definite, if the infant received treatment 
for jaundice, 2) Probable, if there was a diagnosis in the medical record, or 3) Possible, if there 
was only a report in the CGI and no report of treatment. 
Potential misclassification of a confounder 
 In Specific Aim 1, correct adjustment of maternal hypertension in the maternal diabetes 
exposure model, and vice versa, requires knowing accurate time of onset for both conditions 
since one condition can increase risk for the other. With maternal diabetes particularly, a mother 
may be in a diabetic state for a long period of time before she is screened and diagnosed. Date of 
diagnosis was not always available for these conditions and may not accurately represent onset. 
For this reason, we produced two models: 1) where we control for the other condition as 
confounder if present, regardless of time of onset, and 2) where we do not control for the 
confounder. Creating these bounds allowed us to evaluate the effect of confounder 
misclassification on our results. 
G. Power calculations 
Statistical power was calculated using Stata and a Type 1 error rate of α=0.05. Only the 
ASD and POP groups were used for these calculations. Our analysis included 699 cases of ASD 
and 979 population controls, for a total sample size of 1672. In the diabetes exposure group, 
there are a total of 139 mothers exposed according to the CGI. The probability of being exposed 
was Pr(X=1)=139/1533=0.083 and the probability of having the outcome of ASD in the 
unexposed group was Pr(Y=1 l X=0)=630/1533=0.41. In the hypertension in pregnancy exposure 
group, there are a total of 265 mothers exposed according to the CGI. The probability of being 
exposed was Pr(X=1)=265/1667=0.159 and the probability of having the outcome of ASD in the 
unexposed group was Pr(Y=1 l X=0)=554/1402=0.40. In the neonatal jaundice exposure, there 
are a total of 753 infants exposed according to the CGI. The probability of being exposed was 
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Pr(X=1)=753/1678=0.449 and the probability of having the outcome of ASD in the unexposed 
group was Pr(Y=1 l X=0)=358/925=0.39. The statistical power achieved by minimum effect 
sizes is provided in Table 3.8. At some effect sizes, the statistical power is below adequate. This 
is common when studying rare exposures. While we may be limited in making causal inferences 
at this level, the associations that are detected and patterns in the data can still be very 
informative. When we included diagnosis of these complications by medical record and 
abstracted measurements, the number exposed almost doubled.  
Table 3.8. Statistical power obtained to detect an association with ASD by effect size for the 
exposures of maternal diabetes, maternal hypertension, and neonatal jaundice according to CGI  
 Maternal Diabetes Maternal Hypertension Neonatal Jaundice 
Minimum 
Effect Size 
Pr(x=1) Pr 
(Y=1lX=0) 
Statistical 
Power 
Pr(x=1) Pr 
(Y=1lX=0) 
Statistical 
Power 
Pr(x=1) Pr 
(Y=1lX=0) 
Statistical 
Power 
OR=1.25 0.083 0.41 24% 0.159 0.40 38% 0.449 0.39 61% 
OR=1.5 0.083 0.41 63% 0.159 0.40 86% 0.449 0.39 98% 
OR=1.75 0.083 0.41 88% 0.159 0.40 99% 0.449 0.39 ~100% 
OR=2.0 0.083 0.41 97% 0.159 0.40 ~100% 0.449 0.39 ~100% 
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CHAPTER 4: MATERNAL DIABETES AND HYPERTENSIVE DISORDERS IN 
ASSOCIATION WITH AUTISM SPECTRUM DISORDER  
A. Introduction 
  Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental 
disorders characterized by deficits in social interaction and communication, as well as restrictive 
and repetitive patterns of behaviors or interests (239).  Since the 1990’s, the documented 
prevalence of ASD has steadily increased (240). This may be due in part to better diagnosis and 
increased awareness (241-243). The most recent statistics estimate that one in 68 children aged 8 
years is affected with ASD in the U.S. (244). The etiology of ASD remains unknown, but it is 
complex and suspected to involve both genetic and environmental factors (2, 3). Recent studies 
provide evidence for the prenatal period as a sensitive time window for the development of ASD 
(4, 245, 246). Pregnancy complications have been frequently reported in association with the 
development of ASD in the child, (43, 68, 71) with the hypothesis that conditions associated with 
altered fetal nutrient delivery and increased inflammation and oxidative stress can have 
deleterious effects on in utero brain development.  
Maternal diabetes and hypertension are the most common complications of pregnancy. 
With the onset of the obesity epidemic and increasing maternal age in the U.S., the number of 
pregnancies affected by diabetes and hypertension has also increased (17, 247). A few studies 
have shown a positive association between maternal diabetes and hypertension and the 
development of ASD in the child (12, 62, 67, 71, 163, 165-167, 248). However, some studies did 
not model the conditions independently and were limited by small sample sizes. In this analysis, 
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we independently examine maternal diabetes and hypertension using data from a large 
epidemiologic investigation of etiologic risk factors for ASD.  
B. Methods 
Study population  
Participants were from the Study to Explore Early Development (SEED), a multisite 
case-control study with multiple-source ascertainment of children with ASD, children with 
developmental delays or disorders other than ASD (DD) and children sampled from the general 
population (POP) (26). Children in the ASD and DD groups were ascertained through multiple 
agencies and clinical settings that evaluate or serve children with developmental challenges. 
From these sources, we selected children with select special education or International 
Classification for Disease (ICD) codes indicative of autism/ASD or other developmental 
challenge often seen as precursor or co-occurring diagnoses in children eventually diagnosed 
with ASD. This broad diagnostic net for ascertainment ensures that previously diagnosed and 
undiagnosed ASD children were identified (26). State birth records were randomly sampled to 
identify children from the general population (POP group) who were born in the same time 
period and catchment area as children with ASD.    
SEED required eligible children to have been born in and currently (at time of study 
enrollment) reside in one of six study catchment areas (located in California, Colorado, Georgia, 
Maryland, North Carolina, and Pennsylvania) (26). Children also had to be between the ages of 
30 and 68 months of age at the time of in-person assessment, born between September 1, 2003 
and August 31, 2006, and live with a knowledgeable caregiver who was at least 18 years of age, 
spoke English (all sites) and/or Spanish (California and Colorado), and was able to provide legal 
consent. SEED recruited 3,769 participants. For this study, we restricted analyses to the 2,564 
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participants who had a final outcome classification of ASD, DD, or POP and had data available 
on pregnancy complications.  
Data collection 
The SEED data collection protocol is detailed elsewhere (26). SEED collected data on 
family medical history, maternal reproductive health and pregnancy outcomes, and child 
development and behavioral characteristics through telephone interviews, self-administered 
forms, an in-person child developmental assessment, collection of biosamples, and abstraction of 
maternal and child medical records. Limited birth certificate data were also obtained for all 
enrolled participants; however, birth certificate data did not include information on pregnancy 
complications. Data collection was standardized across sites and subject to uniform standards for 
quality data checks.  
Outcome assessment 
All children enrolled in the study were initially screened for autism symptoms using the 
Social Communication Questionnaire (SCQ) (180). As part of the data collection protocol, 
children were administered developmental assessments in-person by a trained clinician and were 
given a more extensive assessment if they screened positive for possible ASD (SCQ score >11), 
were determined to have a previous ASD diagnosis, or were suspected to have ASD based on the 
study clinician’s direct observation. The more extensive assessment of the child included the 
Autism Diagnostic Observation Schedule (ADOS)(181); additionally, their caregivers were 
administered the Autism Diagnostic Interview-Revised (ADI-R) (183). Final classification of 
ASD (yes or no) was based on the findings from these two developmental assessments regardless 
of previous diagnoses (188). More detail about the SEED outcome assessment is described 
elsewhere (26, 188). 
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Ascertainment of maternal hypertension and diabetes 
Multiple SEED instruments included information on maternal hypertension and diabetes: 
1) maternal prenatal care and delivery records; 2) 60-minute telephone interview administered to 
the caregiver that included questions on her health during the index pregnancy; and 3) self-
administered checklists of the mother’s medical history both before and during pregnancy, used 
specifically for diabetes. The mother was classified as having the condition if it was reported 
anywhere in the prenatal medical record or through maternal self-report (either telephone 
interview or on self-checklist). Overall, maternal prenatal care and delivery record data were 
available for 67.3% of study subjects, and maternal self-report data were available for 99.5%.   
Restricting to the 1,711 subjects that had both medical record and self-reported data 
available, substantial or high agreement was found for both maternal diabetes (κ=0.85 95% CI 
0.80, 0.90) and maternal hypertension (κ=0.67 95% CI 0.61, 0.73), based on Landis and Koch 
criteria (249). We thus decided it was appropriate to classify the mother as having the condition 
based on only one data source. Additionally, if the mother reported having the condition by both 
medical record and maternal report, or if the medical record included details establishing that 
criteria on a diagnostic test were met, the mother was further classified as having a ‘Confirmed’ 
condition (see below). 
Using any data source, 246 mothers were classified as having diabetes during pregnancy. 
From these, 45 (18.3%) were classified as having diabetes only by maternal report and 15 (6.1%) 
only by prenatal medical record. Mothers in the diabetes group were classified as having either 
gestational diabetes (GDM) or pre-existing diabetes (including Type 1 and Type 2 Diabetes 
Mellitus). These subclassifications are mutually exclusive. In addition to reported diagnoses of 
GDM, results from oral glucose tolerance tests (OGTT) in the prenatal medical record were used 
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to classify the mother as having GDM. Clinical guidelines by Carpenter and Coustan requiring 
two elevated measurements in the OGTT were used (189). Four mothers (1.6%) were classified 
as having diabetes only by OGTT criteria. Mothers were classified as having ‘Confirmed’ 
diabetes if they met criteria on the OGTT or reported diabetes through both self-report and 
medical record. If only one data source specified a diabetes type but the other confirmed a non-
specified type of diabetes or use of antidiabetic medications (Insulin, Glyburide, or Metformin), 
then the mother was also classified as having ‘Confirmed’ diabetes through both sources. We 
defined ‘No Diabetes’ as not having a diagnosis in the medical record and no maternal report of 
diabetes.  
Additionally, using any data source, 386 mothers were classified as having a hypertensive 
disorder during pregnancy. From these, 102 (26.4%) were classified as having a hypertensive 
disorder only by maternal report and 47 (12.2%) only by prenatal medical record.  Mothers in the 
hypertension group were further classified as having pre-existing chronic hypertension, 
pregnancy induced hypertension (PIH), or a more severe hypertensive disorder of pregnancy, 
including preeclampsia, eclampsia or hemolysis, elevated liver enzymes, and low platelet count 
(HELLP) syndrome. Subclassifications were not mutually exclusive as mothers may have pre-
existing chronic hypertension and then go on to develop preeclampsia, eclampsia, or HELLP 
syndrome in pregnancy. In addition to reported diagnoses, serial blood pressure measurements 
from clinic and hospital visits were used to classify a woman as having a hypertensive disorder, 
depending on the timing of these measurements. Clinical guidelines requiring two separate 
elevated measurements (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg) were used to classify the mother as having pre-existing chronic hypertension (if <20 
weeks gestational age), PIH (if >20 weeks gestational age), or preeclampsia (if  ≥20 weeks 
 59 
gestational age and accompanied by report of protein in urine or use of Magnesium) (192).  
Forty-one (10.6%) mothers were classified as having hypertension only by blood pressure 
measurement criteria. Mothers were classified as having ‘Confirmed’ hypertension if they met 
the blood pressure measurement or reported a hypertensive disorder through both self-report and 
medical record. We defined ‘No Hypertension’ as not having a diagnosis for a hypertensive 
disorder in the medical record and no maternal report of a hypertensive disorder.  
Covariates 
We conducted a thorough literature search to identify covariates that may be potential 
confounders in the association of these maternal conditions with ASD or broader developmental 
delays. For each condition, a Directed Acyclic Graph was used to identify potential confounders 
in order to obtain the least biased estimates (238). Data from birth certificates, prenatal medical 
records, and caregiver phone interview were used to define covariates. Odds ratios and 95% 
confidence intervals were obtained for the effect of each covariate on both the maternal condition 
and the outcome to confirm an association. 
Confounders included maternal age at conception (<35 [referent], ≥ 35 years), maternal 
race/ethnicity (white non-Hispanic [referent] vs. other race/ethnicity), maternal education (high 
school degree or less vs. some college or more [referent]), maternal smoking during pregnancy 
(any vs. none [referent]), and study site (Georgia as referent). For hypertension, parity 
(categorized as first birth [referent], second birth, third or more) and plurality (dichotomized as 
singleton [referent] vs. multiple) were included as additional confounders. For both maternal 
conditions, other potential confounders included having the other condition (diabetes or 
hypertension) and pre-pregnancy body mass index (BMI), categorized using World Health 
Organizations levels for low or normal BMI (referent; <25 kg/m2), overweight (≥ 25 - 30 kg/m2), 
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and obese (≥ 30 kg/m2).  However, because the exact onset of the maternal condition is 
unknown, it is possible that one maternal condition could affect or be affected by the occurrence 
of the other condition or by weight gain; therefore, we treated the other condition and BMI as 
potential confounders (added separately in the adjustment set), also as potential mediators 
(excluded from the adjustment set), and evaluated for effect measure modification.  
Statistical analysis 
We calculated distributions of maternal characteristics by child outcome and maternal 
condition. Multivariable logistic regression models estimated odds ratios (OR) and 95% 
confidence intervals (CI) for the association between maternal conditions and either ASD (vs. 
POP) or DD (vs. POP), adjusting for all confounders. We further adjusted for high pre-
pregnancy BMI and diabetes or hypertension. In unadjusted models, we used the Breslow-Day 
test for homogeneity of the odds ratio with an alpha level α=0.20 for interaction. In adjusted 
models, we obtained stratum-specific effect estimates by BMI category for diabetes and 
hypertension in association with ASD and DD, and tested the assumption of a multiplicative 
model.  
Analyses were replicated in separate samples including only those with a confirmed 
condition and also for subclassifications of the condition. Effect estimates were also obtained for 
ASD with and without intellectual disability (ID) vs. POP, as previous studies have concluded 
that they may be etiologically distinct (167). A Mullen Early Learning Composite Standard 
Score of <70 was used to identify ASD children with ID. All analyses were conducted using 
SAS statistical software, version 9.3 (SAS Institute Inc., Cary, NC). 
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C. Results 
This analysis comprises a sample of 2,564 mother-child pairs enrolled in SEED. The 
study sample included 698 children with ASD, 887 with a non-ASD DD, and 979 from the POP 
group. Compared to our analytic sample, the excluded subset (n=1,062) was less likely to be 
non-White and less likely to have attained a higher education. Mothers of children with ASD and 
DD were older, less likely to be White, less educated, and more likely to smoke during 
pregnancy, have higher pre-pregnancy BMI, or deliver a multiple birth, compared with POP 
mothers (Table 4.1). They were also more likely to have diabetes or a hypertensive disorder, 
compared with POP mothers. Mothers with diabetes were older, less likely to be White, less 
educated, and more likely to smoke during pregnancy and have higher pre-pregnancy BMI.  
Mothers with hypertension were less educated and more likely to smoke, have higher pre-
pregnancy BMI, be primiparous, and pregnant with multiples.  
There were 246 mothers (9.6%) with diabetes during pregnancy; 65 (2.6%) were 
classified as having pre-existing diabetes and 181 (7.1%) with GDM (Table 4.1). Hypertensive 
disorders were present during pregnancy for 386 mothers (15.1%), with 88 (3.4%) classified as 
pre-existing chronic hypertension, 122 (4.8%) with PIH, and 206 (8.0%) with more severe 
hypertensive disorders of pregnancy such as preeclampsia, eclampsia, and HELLP syndrome 
(Table 1). Using the criteria for ‘Confirmed’ condition described above, 151 (5.9%) mothers had 
confirmed diabetes and 231 (9.0%) mothers had a confirmed hypertensive disorder during 
pregnancy.  
In unadjusted analyses, we did not observe an association between maternal diabetes and 
ASD (OR=1.24 [0.89, 1.75]) (Table 4.2). In contrast, maternal diabetes was associated with DD 
(OR=1.47 [1.07, 2.00]). Adjustment for confounders attenuated the effect estimates in both 
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groups (ASD aOR=1.10 [0.77, 1.56]; DD aOR= 1.32 [0.96, 1.82]). Additional adjustment for 
BMI and/or hypertensive disorders further attenuated the effect estimates, but did not materially 
alter the results.  In subgroup analyses, a stronger association was observed with ‘Confirmed’ 
diabetes, particularly in the DD group. Additionally, while stronger associations with ASD and 
DD were observed for mothers with GDM versus pre-existing diabetes, these estimates were 
imprecise with few mothers having pre-existing diabetes.  
We observed associations between hypertensive disorders in pregnancy and ASD 
(OR=1.78 [1.35, 2.35]) and DD (OR=1.67 [1.28, 2.18]) in unadjusted analyses (Table 4.2). After 
adjustment for confounders, effect estimates were slightly attenuated for ASD, but not for DD 
(ASD aOR=1.67 [1.25, 2.23]; DD aOR=1.69 [1.29, 2.23]) and for both remained elevated with 
narrow confidence intervals above the null. Additional adjustment for BMI and/or diabetes did not 
notably alter effect estimates. In subgroup analyses, stronger associations were observed with a 
‘Confirmed’ condition, particularly in the ASD group. A stronger association was also observed 
for pre-existing chronic hypertension and DD, but not for other sub-classifications of hypertensive 
disorders.   
Similar associations were generally observed for maternal diabetes and ASD with ID (vs. 
POP) compared to ASD without ID (vs. POP) (Table 4.3). Associations with hypertensive 
disorders also did not vary greatly among those with ASD with or without ID, remaining 
significant for the broader group, but with imprecise confidence intervals for the pre-existing 
hypertension and PIH subclassifications due to a smaller sample.  
We did not find any evidence of interaction between covariates and the maternal 
conditions of diabetes and hypertensive disorders in association with ASD and DD. We 
evaluated BMI stratum-specific estimates and did not find any departure from multiplicativity in 
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adjusted models (Table 4.4). When we added an interaction term between BMI category and the 
maternal condition, we did not find interaction at p<0.20. Additionally, we did not find 
interaction between the maternal conditions (results not shown). However, confidence intervals 
were very wide due to the small sample size of mothers with both conditions.  
D. Discussion 
We did not observe an association between diabetes in pregnancy and ASD, but there 
was some suggestion of an association between prenatal diabetes and DD. We observed that 
hypertensive disorders during pregnancy were associated with ASD in the child. Similar 
associations were also observed between hypertensive disorders and DD, suggesting a more 
general effect on neurodevelopment rather than specific to ASD processes. Further adjustment 
for BMI and diabetes did not notably materially these associations for hypertensive disorders. 
Overall, stronger associations were seen in mothers with a ‘Confirmed’ condition reported in 
both the medical record and through maternal report, or in a diagnostic test. This may reflect 
some exposure misclassification in mothers without confirmed conditions, or the possibility of 
more severe conditions in pregnancy occurring among mothers in the confirmed group. Limiting 
the analyses to confirmed condition status did not change the interpretation of results for 
hypertensive disorders, but did strengthen the association of diabetes with DD.  
 There are several hypotheses regarding how maternal hypertension may affect fetal 
neurodevelopment, including its association with inflammation and oxidative stress.(22, 120) 
Oxidative stress may bring about cell necrosis or changes to the epigenome, affecting DNA 
methylation and gene expression (120, 123). Additionally, some markers of inflammation are 
known to cross the blood brain barrier (22, 49). Hypertensive disorders are also associated with 
altered fetal nutrient delivery and intrauterine growth restriction (148). Changes in nutrient 
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delivery may alter fetal metabolism and how the fetus grows and develops in utero, thereby 
affecting brain development.  
We observed stronger associations with pre-existing hypertension, particularly with DD. 
This may be related to the timing of the condition during pregnancy and fetal brain development. 
However, some of these mothers (18%) were later diagnosed with a severe hypertensive disorder 
in pregnancy such as preeclampsia, eclampsia, or HELLP, so this group may be composed of 
mothers who had a more severe condition throughout pregnancy. Further study with a larger 
sample of mothers with pre-existing chronic hypertension is needed to explore this association. 
Unlike previous studies suggesting etiologically distinct pathways between ASD with and 
without ID (167), we did not observe differences in the associations for ASD with ID versus 
ASD without ID.    
Previous studies have reported an interaction with high BMI and both maternal diabetes 
and hypertension (12, 166, 167). Comparing BMI stratum-specific estimates, we did not observe 
differences in the association among mothers with pre-pregnancy BMI in the low/normal, 
overweight, or obese categories. Our results suggest that weight may not play a role in the 
association between maternal hypertension and ASD.  
Our results are generally in agreement with other case-control studies (12, 43, 52, 163), 
but there are subtle differences that may be due to the study population and sample size, with 
SEED having the largest number of affected dyads over multiple sites in the U.S.. While our 
results were similar to some cohort studies evaluating this association (8, 67, 71, 165), they 
differed from others (68, 144, 166, 167). Most large cohort studies used less detailed data from 
administrative datasets (68, 166) and/or birth certificates (144, 166). The somewhat rare 
exposures limited power in smaller studies, relative to SEED (166, 167). Additionally, SEED 
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confirmed ASD through a standardized, direct evaluation, instead of relying on ICD-9 codes (68, 
166, 167) or school records (144) that may instead be used to refer the child for further testing 
and not as a final diagnosis. In contrast, all children enrolled in SEED received an in-person 
evaluation to confirm ASD diagnosis with the gold standard instruments, the ADOS and ADI-R. 
Children in the DD and POP group were also screened, reducing outcome misclassification.  
The SEED population-based study design is specifically tailored to identify etiologic 
factors contributing to ASD. Data regarding risk factors are collected in great detail, including 
mailed-in questionnaires, telephone interviews, birth certificates, and medical records, ensuring 
that pregnancy conditions are well-captured. For this study, we also had results from OGTT and 
clinic and hospital blood pressure measurements. These additional data allowed us to confirm the 
maternal condition from medical record and maternal report, reducing the likelihood of exposure 
misclassification.  
Although there are many strengths of this study, some limitations exist. While a number 
of families of potentially-eligible children, did not respond to the SEED invitation letter, 
analyses of data from one SEED site with the most complete data available to assess non-
response indicated that maternal age, education, and race-ethnicity were associated with non-
response but other pregnancy and health variables were not (unpublished analysis). We adjusted 
our findings for all 3 factors aforementioned demographic factors. 
Although diabetes and hypertension are the most common complications in pregnancy, 
they are heterogeneous conditions in their timing and severity, which may affect our ability to 
observe significant associations. Further, our statistical power was reduced for analyses that were 
stratified or were conducted among subclassifications of the conditions or ASD. However, SEED 
is one of the few studies with the detailed data necessary to carry out these analyses. While 
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agreement for data from caregiver interview and medical record was substantial, there may be 
some exposure misclassification due to poor maternal recall or incomplete data in the medical 
record. Additional analyses in mothers with the condition reported in both caregiver interview 
and medical record showed stronger effect estimates, which may be due to misclassification 
when maternal and medical record data were discordant. However, it may also be that more 
severe conditions were more easily recognized and more frequently reported. Further, while we 
aimed to obtain least-biased estimates by adjusting for previously identified confounders, there 
may still be residual confounding by some unknown or unmeasured factors, such as maternal 
diet or genetic predisposition.   
In summary, while we did not find an association between maternal diabetes and ASD, 
we did observe an association with maternal hypertensive disorders and both ASD and DD, 
complementing what has been reported in some studies (8, 12, 43, 52, 67, 71, 163, 165). Further 
exploration of the mechanism by which these associations are present is necessary. A better 
understanding of the role of hypertension on the etiological pathways involved in 
neurodevelopment can potentially lead to improved interventions in high-risk mothers and earlier 
identification of developmental disorders in children.   
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Table 4.1. Distribution of maternal characteristics during pregnancy with index child born 
September 2003-August 2006, by child outcome classification and maternal condition in SEED 
(N=2,564) 
Maternal Characteristics 
 Column percent by child outcome and maternal condition 
Total 
Population 
ASD DD POP Diabetes 
Hypertensive 
Disorders 
 (N=2,564) (n=698) (n=887) (n=979) (n=246) (n=386) 
Maternal Age at Conception 
  < 35 years 89.2 88.7 88.4 90.2 83.7 88.9 
  ≥ 35 years 10.6 11.0 11.4 9.6 15.5 11.1 
Maternal Race/Ethnicity 
  White, non-Hispanic 63.0 55.6 61.0 70.0 58.1 64.0 
  Other 36.5 44.1 38.0 29.6 41.5 35.2 
Maternal Education 
  High school degree or less  18.3 20.2 22.4 13.3 23.6 20.2 
  Some college or more 81.6 79.7 77.6 86.7 76.4 79.8 
Maternal Smoking 
  Yes 13.2 16.2 14.1 10.2 17.5 18.1 
  No 86.0 82.8 85.3 89.0 81.3 81.6 
Pre-pregnancy Body Mass Index      
 <25 kg/m2 (Low/Normal) 1492 58.2 54.7 54.5 64 37 
  25-<30 kg/m2 (High) 603 23.5 24.5 24.9 21.6 28.9 
  ≥30 kg/m2 (Obese) 419 16.3 18.9 17.8 13.18 32.5 
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Parity 
  First birth 43.7 46.7 39.5 45.5 43.5 54.4 
  Second 35.7 34.0 37.0 35.9 36.2 29.5 
  Third or more 20.1 18.8 23.1 18.3 20.3 16.1 
Plurality 
  Singleton 93.4 91.1 92.8 95.5 91.1 88.6 
  Multiple 6.6 8.9 7.2 4.5 8.9 11.4 
Study Site 
  California 15.4 15.3 15.0 15.5 15.5 10.9 
  Colorado 19.4 20.2 17.7 20.2 15.9 24.6 
  Georgia 19.9 19.6 21.7 18.3 18.7 18.1 
  Maryland 14.4 15.5 13.3 14.7 14.6 15.8 
  North Carolina 17.7 14.8 20.5 17.6 22.8 20.7 
  Pennsylvania 13.3 14.6 11.8 13.7 12.6 9.8 
Diabetes in pregnancy       
    No diabetes 90.3 90.3 88.6 91.8 - 81.1 
   Any diabetes 9.6 9.7 11.3 8.0 - 18.9 
       Confirmed 5.9 6.2 7.8 4.0 - 11.1 
       Not confirmed 3.8 3.6 3.6 4.1 - 7.8 
       GDM 7.1 7.5 8.3 5.7 - 11.7 
       Pre-existing diabetes 2.6 2.3 3.0 2.4 - 7.3 
Hypertension in pregnancy 
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  No hypertensive disorder 84.9 81.8 82.9 89.0 70.3 - 
  Any hypertensive disorder 15.1 18.1 17.1 11.0 29.7 - 
       Confirmed 9.0 11.6 10.3 6.0 19.5 - 
       Not confirmed 6.1 6.5 6.9 5.0 10.2  
       Pre-existing hypertension 3.4 3.7 4.9 1.9 3.4 - 
       PIH 4.8 3.9 5.3 5.6 8.1  
       Preeclampsia, eclampsia,   
     HELLP syndrome 
8.0 10.0 8.6 6.1 15.5 - 
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Table 4.2. Associations between maternal diabetes or hypertensive disorders and ASD or DD in 
SEED 
Model 
Exposed n (Column %)  
ASD vs. POP 
OR (95%CI) 
DD vs. POP 
  OR (95% CI) ASD  DD POP 
Maternal Diabetes       
Diabetes unadjusted 68 (9.7) 100 (11.3) 78 (8.0) 1.24 [0.89, 1.75] 1.47 [1.07, 2.00] 
Diabetes adjusteda 65 (9.5) 97 (11.1) 78 (8.1) 1.10 [0.77, 1.56] 1.32 [0.96, 1.82] 
Diabetes adjusteda + BMI, HTN 64 (9.5) 94 (11.1) 78 (8.2) 0.96 [0.67, 1.39] 1.19 [0.86, 1.65] 
  Confirmed diabetesa 42 (6.3) 69 (8.2) 39 (4.2) 1.45 [0.92, 2.29] 1.86 [1.23, 2.80] 
  Pre-existing diabetesa 15 (2.4) 26 (3.3) 23 (2.5) 0.86 [0.44, 1.70] 1.13 [0.63, 2.02] 
  GDMa 50 (7.2) 56 (5.9) 72 (8.5) 1.20 [0.80, 1.80] 1.42 [0.98, 2.05] 
Maternal Hypertensive Disorders      
Hypertension unadjusted 126 (18.1) 152 (17.1) 108 (11.0) 1.78 [1.35, 2.35] 1.67 [1.28, 2.18] 
Hypertension adjustedb 125 (18.2) 150 (17.3) 107 (11.1) 1.67 [1.25, 2.23] 1.69 [1.29, 2.23] 
Hypertension adjustedb + BMI, DM  125 (18.5) 148 (17.5) 107 (11.2) 1.56 [1.16, 2.11] 1.59 [1.20, 2.12] 
  Confirmed hypertensionb 81 (12.6) 59 (6.4) 89 (11.0) 2.02 [1.40 2.91] 1.85 [1.30, 2.63] 
  Pre-existing hypertensionb 26 (4.4) 43 (5.7) 19 (2.2) 1.67 [0.90, 3.11] 2.44 [1.39, 4.27] 
  PIHb 38 (6.3) 47 (6.1) 37 (4.1) 1.45 [0.90, 2.33] 1.51 [0.96, 2.37] 
  Preeclampsia, eclampsia, and HELLPb 70 (11.1) 60 (6.5) 74 (9.3) 1.61 [1.11, 2.34] 1.41 [0.98, 2.04] 
 
 
 
  
a. Adjusted for maternal age, maternal race/ethnicity, maternal education, maternal smoking, and study site. 
b. Adjusted for above (a.) plus plurality and parity.  
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Table 4.3. Associations between maternal diabetes or hypertensive disorders and ASD with 
(n=258) and without (n=429) intellectual disabilities (ID) in SEED  
Model 
Exposed n (Column %) ASD with ID 
vs. POP  
aOR (95% CI) 
ASD without ID 
vs. POP  
aOR (95% CI) 
ASD 
with ID 
ASD 
without ID 
POP 
Maternal Diabetes      
Diabetesa 77 (18.0) 45 (17.4) 108 (11.0) 1.23 [0.82, 1.84] 1.00 [0.60, 1.66] 
   Pre-existing diabetesa 44 (10.4) 21 (8.2) 78 (8.1) 0.89 [0.41, 1.98] 0.83 [0.31, 2.21] 
   GDMa 76 (18.1) 45 (17.6) 107 (11.1) 1.38 [0.87, 2.18] 1.07 [0.60, 1.92] 
Maternal Hypertensive Disorders      
Hypertensionb 34 (8.3) 16 (6.4) 56 (5.9) 1.67 [1.19, 2.35] 1.61 [1.10, 2.38] 
   Pre-existing hypertension
b
 18 (5.0) 7 (3.2) 19 (2.2) 1.69 [0.84, 3.39] 1.52 [0.63, 3.69] 
   PIHb 21 (5.8) 15 (6.6) 37 (4.1) 1.33 [0.75, 2.37] 1.52 [0.81, 2.84] 
   Preeclampsia, eclampsia, HELLPb 41(10.7) 27 (11.3) 60 (6.5) 1.61 [1.04, 2.49] 1.61 [0.99, 2.62] 
 
 
 
 
  
a. Adjusted for maternal age, race/ethnicity, maternal education, maternal smoking, and study site. 
b. Adjusted for above (a.) plus plurality and parity. 
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Table 4.4. Stratum-specific effect estimates for maternal diabetes and hypertensive disorders for 
three strata of maternal pre-pregnancy BMI in SEED 
Model / Strata  
ASD vs. POP        
aOR (95% CI) 
p-value for 
interaction 
DD vs. POP 
aOR (95% CI) 
p-value for 
interaction 
Maternal Diabetes 
BMI: low, normal (<25 kg/m2)a 0.95 [0.71, 1.27] Reference 1.23 [0.97, 1.57] Reference 
BMI: overweight (25-<30 kg/m2)a 0.98 [0.70, 1.35] 0.913 0.96 [0.71, 1.31] 0.213 
3 
BMI: obese (≥30 kg/m2)a 1.11 [0.80, 1.53] 0.490 1.11 [0.81, 1.51] 0.594 
Maternal Hypertensive Disorders 
BMI: low, normal (<25 kg/m2) b 1.35 [1.05, 1.64] Reference 1.34 [1.09, 1.66] Reference 
BMI: overweight (25-<30 kg/m2)b 1.23 [0.93, 1.64] 0.734 1.30 [0.99, 1.70] 0.844 
BMI: obese (≥30 kg/m2)b 1.17 [0.90, 1.54] 0.538 1.14 [0.87,1.48] 0.324 
 
 
 
a. Adjusted for maternal age, race/ethnicity, maternal education, maternal smoking, and study site. 
b. Adjusted for above (a.) plus plurality and parity. 
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CHAPTER 5: NEONATAL JAUNDICE IN ASSOCIATION WITH AUTISM 
SPECTURM DISORDER 
A. Introduction  
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by 
persistent impairment in social interaction and communication, and restrictive and repetitive 
patterns of behaviors, interests, or activities (239). In 2012, the prevalence of ASD in the U.S. 
was estimated to be 1 in 68 children aged 8 years (1). ASD is a heterogeneous disorder, and its 
etiology is suspected to involve both genetic and environmental factors (2, 9). While 
environmental factors associated with ASD are not well understood, recent studies have 
implicated several exposures in the perinatal period (13, 52, 55). 
Jaundice, a yellow discoloration of the skin and the sclera of the eyes, occurs in about 
half of newborn infants and most preterm infants, usually as a result of increased bilirubin from 
the breakdown of fetal hemoglobin after birth (168). While jaundice typically resolves in the first 
week of life (169, 170), bilirubin can cross the blood brain barrier and may have toxic effects on 
the developing brain (170, 250, 251). Hyperbilirubinemia in the neonatal period has been 
associated with intellectual disability, cerebral palsy, and brain dysfunction in children (250, 
252).  
     Some studies have reported an association among neonatal jaundice and 
hyperbilirubinemia and ASD (52, 105, 174-176), while others have reported no association (10, 
177). The inconsistent results may be partly due to differences in methods of data collection and 
classification of jaundice. Jaundice occurs more frequently among infants born preterm (14), and 
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preterm birth has also been consistently associated with increased risk of ASD. Yet, few studies 
have addressed the role of gestational age in exploring associations between jaundice and ASD. 
To address the limitations of previous studies, we analyzed data from the Study to Explore Early 
Development (SEED), a multisite case-control study with extensive data from the perinatal 
period, to investigate the association between neonatal jaundice and ASD.  
B. Methods 
Study population 
The Study to Explore Early Development (SEED) is a multisite case-control study of 
children with ASD, children with developmental delays or disorders other than ASD (DD), and 
children sampled from the general population (POP) (26). Children in the ASD and DD groups 
were ascertained through multiple school systems, agencies, and clinical settings that evaluate or 
serve children with developmental challenges, based on a broad range of special education or 
International Classification for Disease (ICD) codes indicative of autism/ASD or other 
developmental challenge. State birth records were randomly sampled to identify children from 
the general population who were born in the same time period and catchment area as children 
with ASD.   SEED participants were born between September 1, 2003 and August 31, 2006 and 
at the time of enrollment resided in one of six study catchment areas (California, Colorado, 
Georgia, Maryland, North Carolina, and Pennsylvania). The children were required to be 30 
through 68 months of age at the time of in-person assessment and living with a knowledgeable 
caregiver who spoke English (or Spanish in California and Colorado) and who was at least 18 
years of age and able to provide legal consent.  SEED recruited 3,769 participants. For this study, 
we restricted analyses to the 2,561 participants who had data available on neonatal complications 
and had a final outcome classification of ASD, DD, or POP. 
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Data collection 
Details on the SEED data collection protocol are provided elsewhere (26). Briefly, SEED 
collected detailed data on maternal reproductive health and pregnancy outcomes through a 
telephone interview, abstraction of prenatal, neonatal, and pediatric medical records, and linkage 
with birth certificates.  Data on child development and behavior were obtained through telephone 
interviews and in-person child developmental assessment, as described below.  
Outcome Assessment 
We used the Social Communication Questionnaire (SCQ) (180) to screen all children for 
autism symptoms during the invitation phone call. Children who screened positive for possible 
ASD (SCQ score >11), had a previous ASD diagnosis, or were suspected to have ASD based on 
the study clinician’s direct observation, were given a more extensive developmental assessment. 
The more extensive assessment included clinical observation of the child using the Autism 
Diagnostic Observation Schedule (ADOS)(181) and a structured interview administered to their 
caregivers, the Autism Diagnostic Interview-Revised (ADI-R)(183). Final ASD classification 
was based on the results from these two developmental assessments regardless of previous 
diagnoses (188).  
As part of the protocol, study clinicians administered the Mullen Scales of Early Learning 
to all children as a general developmental assessment. We used the Mullen Scales of Early 
Learning Composite Standard Score to identify children with ASD and intellectual disability (ID; 
score <70) or ASD without ID (score ≥70). More detail about the SEED outcome assessment is 
available elsewhere (26, 188). 
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Ascertainment of neonatal jaundice 
Information on neonatal jaundice was obtained from the maternal interview and the 
neonatal medical record. Data from pediatric medical records were also obtained for the first 28 
days of life. The infant was classified as having neonatal jaundice if a diagnosis or treatment for 
jaundice was recorded in the medical record or through maternal report. Treatment for neonatal 
jaundice included phototherapy (bili light or blanket) or, in severe cases, exchange transfusion. 
We classified neonatal jaundice as: 1) Definite, if treatment for neonatal jaundice was reported in 
either the medical record or maternal interview, 2) Probable, if a diagnosis of jaundice was 
available in the medical record, but treatment was not reported, or 3) Possible, if neonatal 
jaundice was only reported through maternal interview, or 4) No neonatal jaundice, if an infant 
had no report of jaundice or treatment for jaundice in the medical record or maternal interview. 
Indicator variables were created for these mutually exclusive categories with the referent group 
of no neonatal jaundice.  
Bilirubin measurements were collected from the neonatal medical record when available. 
Hyperbilirubinemia, defined as a total serum bilirubin measurement above the 95th percentile, 
was classified according to the Bhutani nomogram. The Bhutani nomogram is used among 
infants born ≥35 weeks gestation and evaluates the total serum bilirubin measurement relative to 
the age of the infant (in 12-hour increments). The nomogram defines 95th percentile, 75th 
percentile, and 40th percentile tracks for bilirubin measurements and designates the categories 
above as high-risk, high-intermediate risk, and low-intermediate risk zones, respectively, for 
significant hyperbilirubinemia (obtaining a subsequent measurement in the 95th percentile) (173, 
193). We created indicator variables for these mutually exclusive categories, and defined the 
referent group as infants with no bilirubin measurement or with bilirubin measurements below 
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the 40th percentile, and no neonatal jaundice indicated in the medical record or maternal 
interview. The referent group includes infants that did not have a bilirubin test ordered because 
they had no visible jaundice. A variable encompassing any bilirubin level above the 40th 
percentile was also created to characterize infants with an elevated bilirubin measurement.  
Covariates 
Confounders of the association between neonatal jaundice and ASD or DD were 
identified through a thorough literature. A directed acyclic graph was used to determine a 
minimally sufficient set of confounders in order to obtain the least biased estimates of 
association (238). Data from prenatal and neonatal medical records, birth certificates, and 
maternal interview were used to define covariates.  
Confounders included maternal age at conception (20 years, 20-34 (referent), ≥ 35 years), 
maternal education (high school degree or less vs. some college or more), parity (nulliparous 
(referent), primiparous, multiparous), diabetes in pregnancy (vs. no diabetes), infant sex (male 
vs. female), gestational age, infant race/ethnicity, and study site. Study sites included: Georgia 
(referent), California, Colorado, Maryland, North Carolina, and Pennsylvania.    
Infant race/ethnicity was classified by combining maternal and paternal race as reported 
on the maternal interview, or the birth certificate when maternal interview data were missing. If 
the parents were the same race the infant was classified as White (referent), Black, Other 
(including Asian, Pacific Islander, or Native American). If both parents identified as Hispanic, 
the infant was classified as Hispanic, regardless of reported parental race. Additionally, an infant 
was classified as Multiracial, white (if one parent was White and the other was not) or 
Multiracial, other (if the parents were of different non-White races), allowing for the 
consideration of differences in jaundice diagnosis affected by skin tone.  
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Gestational age was classified according to clinical practice guidelines from the 
American Academy of Pediatrics (173) specifically for assessing neonatal jaundice: <35 weeks 
completed gestation, 35-37 weeks completed gestation, or ≥38 weeks of completed gestation.    
Statistical Analyses  
We calculated descriptive statistics to compare maternal and perinatal characteristics by 
child outcome and neonatal jaundice. Multivariable logistic regression models estimated odds 
ratios (OR) and 95% confidence intervals (CI) for the association between neonatal jaundice and 
either ASD (vs. POP) or DD (vs. POP), adjusting for all confounders (aOR) noted above.  
In addition, we estimated the association between subcategories of neonatal jaundice 
(definite, probable, and possible) and ASD or DD. We also used logistic regression models to 
estimate the association between elevated bilirubin measurement levels and child outcome 
restricting to infants born ≥35 weeks, defining any elevated bilirubin as >40th percentile and also 
evaluating the association among subcategories of bilirubin elevated at the 95th, 75th, and 40th 
percentiles.  
We tested the assumption of homogeneity of the association across strata of gestational 
age. We included interaction terms in the model and evaluated significance at α=0.20. We also 
obtained stratum-specific effect estimates from the interaction model for the association between 
neonatal jaundice and ASD/DD and for the association between elevated bilirubin and ASD/DD, 
restricting to infants ≥35 weeks gestation. Furthermore, we also assessed whether there were any 
differences in the association between neonatal jaundice and ASD with and without ID to 
evaluate the potential for these phenotypes to be etiologically distinct. We evaluated this 
association across strata of gestational age and among subcategories of neonatal jaundice.  
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We could not determine the eligibility of all families we attempted to recruit because 
SEED recruited participation from multiple sources and multiple sites.  One site had more data 
available to assess the generalizability of their sample.  This assessment found response to be 
related to maternal age, education and race-ethnicity, but unrelated to available pregnancy and 
health variables.  Accordingly, all analyses include adjustment for maternal age, education, and 
race.  All analyses were conducted using SAS statistical software, version 9.3 (SAS Institute 
Inc., Cary, NC). 
C. Results 
 A total of 2,561 mother-child pairs enrolled in SEED were included in this analysis. The 
study sample was comprised of 697 children with ASD, 886 with a non-ASD DD, and 978 from 
the POP group. Compared to POP children, children with ASD and DD were more likely to have 
older and less educated mothers, and were more likely to be multiple births, born earlier, male, 
and non-White (Table 5.1). Children with neonatal jaundice were more likely to have been born 
earlier and to have had mothers who were older at conception and who had diabetes in 
pregnancy. A total of 1,323 children were excluded because they had missing data on neonatal 
jaundice or had a developmental disorder with some characteristics for ASD but not sufficient to 
meet diagnostic criteria.  Compared to the analytic sample, children in the excluded subset were 
more likely to be White and less likely to have a mother who attained a higher education.  
In our sample, 1,239 infants (48.4%) were classified as having neonatal jaundice 
according to either the maternal interview or medical records (709 (57.2%) by both sources, 235 
(19%) by maternal interview only, and 295 (23.8%) by neonatal medical record only). Of these, 
50.5% were classified as having definite jaundice, 30.5% with probable jaundice, and 19% with 
possible jaundice. There were 271 children (16.9% of 1,604 with a completed medical record) 
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born ≥35 weeks with any elevated bilirubin (bilirubin above the 40th percentile). Of these, 
bilirubin levels were above the 95th percentile for 88 (5.5%), between the 75th-95th percentile for 
78 (4.9%), and between 40th-75th percentiles for 105 (6.5%). There were 143 children with a 
bilirubin measurement below the 40th percentile; those children along with an additional 1,088 
who had no measured bilirubin or record of jaundice comprised the referent group of no 
hyperbilirubinemia.  
The association between any neonatal jaundice and ASD and DD risk varied across strata 
of gestational age and an interaction term for jaundice and gestational age was significant in all 
strata; thus all results are presented by gestational age stratum (Table 5.2).  In unadjusted 
analyses, we observed positive associations between neonatal jaundice and both ASD and DD 
risk only among children born <38 weeks gestation (Table 5.2). After adjustment, risk estimates 
remained elevated for children born <35 weeks gestation with ASD (aOR=3.05 [1.00, 9.25]) and 
DD (aOR=2.23 [0.96, 5.19]). For children born 35-37 weeks, a positive but weaker association 
was observed with ASD (aOR=1.83 [1.05, 3.19] yet stronger association with DD (aOR=3.34 
[1.99, 5.61]). Jaundice was not associated with ASD or DD among those born ≥38 weeks.   
We also further estimated the association based on three subclassifications of neonatal 
jaundice. Among those with definite (treated) jaundice, stronger associations were observed in 
the 35-37 weeks stratum with ASD (aOR=2.19 [1.26, 3.82]) and DD (aOR=3.76 [2.31, 6.12]). In 
practice, most infants with jaundice before 35 weeks gestation received treatment; therefore, 
fewer infants were classified with probable or possible jaundice and those results were unstable. 
We observed positive but weaker associations with probable jaundice and possible jaundice and 
ASD/DD in the 35-37 weeks stratum. Jaundice was not associated with ASD or DD among 
infants born ≥38 weeks for any subcategories. 
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Our results show slightly stronger patterns of association between neonatal jaundice and 
ASD without ID among those <38 weeks gestation (Table 5.3).  However, the pattern of no 
associations among those ≥38 weeks remained. The association between elevated bilirubin and 
ASD and DD also differed by gestational age and was mostly limited to those born 35-37 weeks 
gestation and not those born ≥38 weeks (Table 5.4).  The associations were strongest for elevated 
bilirubin at the 40th and 95th percentiles, however, the sample sizes in these strata are small and 
the confidence intervals are wide. No associations were seen at the 75th percentile of bilirubin 
levels.  
D. Discussion  
Our results show an association between neonatal jaundice and both ASD and DD among 
infants born between 35-37 weeks gestation. The association with both ASD and DD suggests a 
more general effect on neurodevelopment rather than on processes specific to ASD.  Jaundice 
was associated with neurodevelopment among infants born <35 weeks, however, we had limited 
statistical power to assess associations in this smaller subgroup. We did not observe any 
association between neonatal jaundice and either ASD or DD among infants born ≥38 weeks 
gestation. Our analysis is unique in that information on neonatal jaundice was collected through 
medical record, maternal report, and abstracted laboratory measurements. Despite small sample 
sizes in some strata in our study, the large SEED population made it possible to assess for 
interaction between gestational age and neonatal jaundice with reasonable power compared to 
other studies (176-178). Our results were consistent with some previous studies (105, 174, 178), 
but not with others (175-177).  
In our study, the magnitude of the association between jaundice and ASD/DD varied 
according to the jaundice definition. Among subcategories of neonatal jaundice, definite and 
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probable jaundice were associated with ASD and DD among infants born between 35-37 weeks. 
We observed weak or no association with possible jaundice, which was defined by maternal 
report of jaundice only. The possible jaundice group may have higher potential for 
misclassification because the diagnosis was not confirmed in the medical record and the 
condition was not severe enough to warrant treatment.  
 Previous studies of bilirubin levels differed in how they defined high bilirubin. This is the 
first study to use the Bhutani nomogram to classify bilirubin levels, a method that is 
recommended in current medical practice (173). The Bhutani nomogram is used among infants 
born ≥35 weeks gestation to evaluate bilirubin measurements relative to the age of the infant (in 
12-hour increments) and tracks zones for the 95th percentile, 75th percentile, and 40th percentile 
measurements, designating them as high-risk, high-intermediate risk, and low-intermediate risk 
(respectively) for any significant hyperbilirubinemia (173, 193). While our findings suggest an 
underlying association with bilirubin and ASD, confidence intervals were imprecise due to small 
sample sizes, as fewer children had bilirubin measurements available from the medical record.  
However, elevated bilirubin was associated with DD among infants born between 35-37 weeks. 
A stronger association may be expected with higher bilirubin levels due to its potential for 
neurotoxicity, however we did not observe this in our study. Instead, associations were strongest 
for lower bilirubin levels (40th percentile) and DD among infants born between 35-37 weeks.  
Previous studies show that neonatal jaundice is more common and may be more 
prolonged in preterm infants compared to term infants (253-255) and preterm birth is strongly 
associated with ASD and DD (54, 256). While we did not have the data to evaluate the length of 
time an infant had elevated bilirubin levels, future studies should be designed to determine if the 
association we observed with neonatal jaundice and ASD/DD may be due to a prolonged 
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exposure of bilirubin crossing the blood-brain barrier. It is also possible that infants with lower 
bilirubin were less likely to be treated and therefore could have had a prolonged exposure, which 
would explain the stronger associations we observed in the 40th percentile group compared to the 
higher bilirubin level groups, but we did not have data to further investigate this explanation. 
Larger populations and more detailed, serial data on exposure to elevated bilirubin are necessary 
to more precisely estimate the association and establish a causal mechanism.   
SEED is the first study to account for interaction between gestational age and jaundice 
and to provide stratum-specific effect estimates by gestational age; prior studies restricted their 
analyses to term infants or adjusted for preterm birth as a confounder. Still, the health of infants 
with jaundice, especially preterm infants with jaundice, can be more complex than for term 
infants with no signs of jaundice. There may be several unknown or unmeasured factors that 
commonly co-occur with jaundice in preterm infants that may contribute to brain development, 
which include other perinatal and neonatal complications and how such complications are treated 
or managed. This presents a potential for uncontrolled confounding and should continue to be 
explored.   
Inconsistencies between our results and prior studies may also be due to differences in 
how ASD was ascertained or defined. Most previous studies (52, 174, 177, 178) relied on ICD-9 
codes or insurance databases that may reflect treatment codes that are not necessarily consistent 
with a final diagnosis. SEED confirmed ASD through in-person evaluation and all children had 
to meet criteria on the ADOS and ADI-R to obtain a final ASD classification, reducing the 
potential for outcome misclassification and providing some insight that jaundice was associated 
with development more generally, and not necessarily specifically associated with ASD.   
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In conclusion, we observed associations between neonatal jaundice and ASD and DD in 
infants born <38 weeks gestation, but not among infants born at term (≥38 weeks). This 
association may be due to delayed clearance of bilirubin in preterm infants, which deserves 
further investigation. Future studies should further explore the complexity of other neonatal 
conditions that accompany jaundice, and treatment profiles for jaundice, in association with 
ASD. While primary treatment of such conditions are a priority for neonatologist, the timely 
reduction of jaundice could have the added benefit of reducing subsequent neurodevelopmental 
effects.  In addition, monitoring children with perinatal experiences that include known risk 
factors associated with ASD and developmental disabilities may lead to earlier diagnosis and 
treatment, which can improve long-term outcomes.  
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Table 5.1. Distribution of maternal and infant characteristics by outcome classification and 
jaundice type in children born September 2003-August 2006 enrolled in SEED (N=2,561) 
Maternal Characteristics 
 Column percent by child outcome and neonatal condition 
Total 
Population 
ASD DD POP 
Jaundice 
Diagnosis 
Hyperbili-
rubinemia 
 (N=2,561) (n=697) (n=886) (n=978) (n=1,239) (n=88) 
Maternal Age at Conception 
<20 years 6.2 5.6 6.8 6.1 5.0 1.14 
  20-<35 years 83.2 83.4 81.8 84.3 83.6 85.23 
  ≥ 35 years 10.6 11.1 11.4 9.6 11.4 13.6 
Maternal 
Education
  
      
  High school degree or less 14.5 16.2 18.0 10.1 12.4 15.9 
  Any college 59.3 62.0 56.4 60.0 62.5 58.0 
  Graduate school 26.2 21.7 25.6 29.8 25.1 25.0 
Parity       
  First birth 44.0 47.1 39.7 45.6 46.6 41.5 
  Second 35.9 34.2 37.0 36.1 33.3 38.4 
  Third or more 20.15 18.8 23.3 18.3 20.2 23.9 
Plurality       
 Singleton 94.0 91.8 93.2 96.1 90.4 95.5 
 Multiple 6.1 8.2 6.8 3.9 9.6 4.6 
Maternal Diabetes       
  Yes 9.6 9.8 8.0 11.3 11.4 14.8 
Gestational Age       
 <35 weeks gestation 8.7 8.8 12.3 5.3 14.9 0 
  35-37 weeks gestation 16.0 17.1 19.5 12.1 21.2 28.4 
  ≥38 weeks gestation 75.3 74.2 68.2 82.6 63.9 71.6 
Infant Race/Ethnicity       
  White, non-Hispanic 60.7 53.8 59.6 66.7 62.7 59.1 
  Black, non-Hispanic 16.5 20.7 16.9 13.2 14.3 13.6 
  Hispanic 7.2 7.3 8.8 5.6 6.1 10.2 
  Asian 3.9 6.0 3.6 2.6 4.0 3.4 
  Multiracial, white 6.1 6.2 5.5 6.5 6.5 6.8 
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  Multiracial, other 5.6 6.0 5.4 5.5 6.4 6.8 
Child Sex       
    Male 64.5 82.1 63.0 53.4 64.5 62.5 
Study Site       
  California 15.4 15.2 15.0 15.8 12.4 14.8 
  Colorado 19.5 20.2 17.8 20.4 22.1 22.7 
  Georgia 19.8 19.7 21.7 18.1 17.0 10.2 
  Maryland 14.4 15.5 13.3 14.5 15.4 12.5 
  North Carolina 17.8 14.8 20.5 17.6 21.6 20.5 
  Pennsylvania 13.2 14.6 11.6 13.7 11.5 19.3 
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Table 5.2. Stratum-specific estimates by gestational age for the association between neonatal jaundice and ASD or DD in SEED 
 Jaundice N Unadjusted OR (95% CI) Adjusted OR (95% CI) 
ASD DD POP  ASD vs. POP DD vs. POP ASD vs. POP DD vs. POP 
Any neonatal jaundice:   
    <35 weeks gestation 54 93 38 1.69 (1.02, 2.70)* 1.46 (0.98, 2.19) 3.05 (1.00, 9.25) 2.23 (0.96, 5.19) 
   35-37 weeks gestation 72 130 60 1.22 (0.94, 1.57)* 1.71 (1.33, 2.19) 1.83 (1.05, 3.19) 3.34 (1.99, 5.61) 
   ≥38 weeks gestation 213 248 331 1.00 (0.90, 1.12)* 1.00 (0.90, 1.12) 0.97 (0.76, 1.24) 1.07 (0.85, 1.33) 
Definite jaundice:  
  <35 weeks gestation 49 89 36 1.65 (1.00, 2.73)* 1.47 (0.98, 2.21) 1.66 (0.99, 2.79) 3.80 (2.41, 6.00) 
  35-37 weeks gestation 41 75 25 1.42 (1.04, 1.95)* 2.01 (1.49, 2.72) 2.19 (1.26, 3.82) 3.76 (2.31, 6.12) 
   ≥38 weeks gestation 84 108 119 1.05 (0.90, 1.23)* 1.10 (0.95, 1.28) 1.01 (0.73, 1.42) 1.28 (0.95, 1.73) 
Probable jaundice:  
   <35 weeks gestation 4 3 1 - - - - 
  35-37 weeks gestation 24 35 21 1.19 (0.84, 1.69)* 1.50 (1.07, 2.10) 1.95 (1.01, 3.80) 2.49 (1.39, 4.47) 
   ≥38 weeks gestation 66 90 134 0.88 (0.75, 1.04)* 0.95 (0.82, 1.10) 0.83 (0.58, 1.18) 0.98 (0.72, 1.34) 
Possible jaundice:  
   <35 weeks gestation 1 1 1 - - - - 
   35-37 weeks gestation 7 20 14 0.79 (0.48, 1.29)* 1.39 (0.94, 2.06) 0.60 (0.22, 1.63) 2.00 (0.97, 4.11) 
   ≥38 weeks gestation 63 50 78 1.13 (0.94, 1.35)* 0.93 (0.77, 1.12) 1.22 (0.83, 1.79) 0.87 (0.59, 1.28) 
Adjusted for maternal age, maternal education, maternal diabetes, parity, plurality, infant sex, infant race/ethnicity, and study site. 
Interaction term for gestational age and jaundice was significant at α<0.20 in all strata.   
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Table 5.3. Stratum-specific estimates by gestational age for the association between neonatal jaundice and ASD with or without ID 
SEED 
 Jaundice N ASD with ID  
aOR (95% CI) 
ASD without ID  
aOR (95% CI) ASD with ID ASD without ID POP 
Any neonatal jaundice:  
   <35 weeks gestation 28 24 38 1.97 (0.59, 6.60) 8.17 (0.95, 70.28) 
  35-37 weeks gestation 45 26 59 1.96 (1.03, 3.71) 1.80 (0.84, 3.88) 
  ≥38 weeks gestation 130 79 331 0.99 (0.74, 1.32) 0.95 (0.67, 1.33) 
Definite jaundice:  
  <35 weeks gestation 25 22 36 1.30 (0.69, 2.45) 2.47 (1.29, 4.74) 
  35-37 weeks gestation 23 17 25 2.05 (1.08, 3.92) 2.77 (1.37, 5.60) 
   ≥38 weeks gestation 51 32 119 1.01 (0.68, 1.51) 1.10 (0.69, 1.75) 
Adjusted for maternal age, maternal education, maternal diabetes, parity, plurality, infant sex, infant race/ethnicity, and study site.  
Interaction term for gestational age and jaundice was significant at α<0.20 in all strata. 
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Table 5.4. Stratum-specific estimates by gestational age for the association between elevated bilirubin levels and ASD or DD in 
SEED  
 Jaundice N Unadjusted OR (95% CI) Adjusted OR (95% CI) 
ASD DD   POP  ASD vs. POP DD vs. POP ASD vs. POP DD vs. POP 
Any elevated bilirubin:  
    35-37 weeks gestation 28 39 19 1.29 (0.91, 1.81) 1.57 (1.13, 2.19)* 1.94 (0.94, 4.01)* 2.15 (1.12, 4.14)* 
 
   ≥38 weeks gestation 
 
55 52 78 1.05 (0.87, 1.27) 0.93 (0.77, 1.12)* 1.06 (0.71, 1.58)* 0.90 (0.62, 1.33)* 
95th Percentile:   
   35-37 weeks gestation 8 12 5 1.34 (0.75, 2.41) 1.70 (0.98, 2.96) 2.39 (0.66, 8.70) 2.41 (0.78, 9.61) 
 
   ≥38 weeks gestation 
 
17 26 20 1.15 (0.83, 1.61) 1.30 (0.96, 1.75) 1.14 (0.56, 2.32) 1.68 (0.91, 3.10) 
75th Percentile:  
   35-37 weeks gestation 8 11 8 1.06 (0.63, 1.79) 1.29 (0.79, 2.10)* 1.09 (0.37, 3.21) 1.43 (0.53, 3.84) 
 
   ≥38 weeks gestation 
 
16 11 24 1.02 (0.74, 1.41) 0.77 (0.54, 1.11)* 1.15 (0.57, 2.34) 0.73 (0.35, 1.55) 
40th Percentile:  
   35-37 weeks gestation 12 16 6 1.50 (0.89, 2.52)* 1.79 (1.08, 2.97)* 2.99 (0.97, 9.22)* 2.92 (1.05, 8.17)* 
 
   ≥38 weeks gestation 
22 15 34 1.01 (0.76, 1.33)* 0.76 (0.55, 1.03)* 0.94 (0.52, 1.71)* 0.56 (0.30, 1.05)* 
Adjusted for maternal age, maternal education, maternal diabetes, parity, plurality, infant sex, infant race/ethnicity, and study site.  
*Interaction term for gestational age and jaundice was significant at α<0. 20
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CHAPTER 6: DISCUSSSION 
A. Summary 
 In the past two decades the prevalence of ASD has increased and more attention has 
focused on discovering etiological pathways associated with ASD. Despite evidence that 
environmental exposures during the prenatal and neonatal period play a role in the development 
of ASD, few independent risk factors have been identified. This study examines the associations 
between the most common prenatal and neonatal complications and ASD.  
We use data from the Study to Explore Early Development, a large multi-site case-
control study designed to identify etiological risk factors for ASD. Information regarding 
prenatal and neonatal risk factors is collected in SEED from medical records, caregiver phone 
interviews, questionnaires, and birth certificates. All children are screened and clinically 
evaluated to confirm ASD or a secondary outcome group classified with non-ASD 
developmental delay. These outcome groups are compared to children ascertained from the 
population matched on age and location through birth records.  
This work had two specific aims: 1) to examine the associations between prenatal 
complications, specifically maternal diabetes and hypertension, and ASD, and 2) to examine the 
association between neonatal complications, specifically neonatal jaundice, and ASD. 
Comparing these associations to DD vs. POP allows us to determine if these associations are 
specific to ASD. While some studies have shown a positive association between these 
complications and ASD, others have shown no association, and their role in the development of 
ASD is still unknown. However, few studies had large sample sizes to examine these 
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complications and most did not model these conditions independently. Our analysis addresses 
limitations from previous studies and tries to identify possible etiological mechanisms for ASD 
for further study.  
B. Prenatal complications and ASD 
In our first aim, we examined the association between maternal diabetes and hypertension 
and ASD. Diagnoses of any diabetes or hypertensive disorder during pregnancy were identified 
from prenatal medical records, caregiver phone interview, and mailed-in questionnaires (for 
diabetes). In addition, serial blood pressure measurements from clinic and hospital records were 
available for hypertension as well as results from diagnostic tests for gestational diabetes.  
Our analysis did not show an association between diabetes in pregnancy and ASD, but 
did show an association with maternal hypertensive disorders and ASD. Additionally, maternal 
diabetes and hypertensive disorders were both associated with DD. While we did observe an 
association with diabetes and hypertension and neurodevelopmental disorders, only hypertension 
was associated with ASD. We did not observe notable differences in the associations for ASD 
with ID versus ASD without ID, contrary to previous studies (167).  
There are several possible biological mechanisms to explain how diabetes and 
hypertensive disorders in pregnancy may affect fetal neurodevelopment. A plausible explanation 
is through inflammation and oxidative stress that occurs with chronic hypertension (22, 120). 
Inflammation can lead to changes in DNA methylation and gene expression (Rose et al., 2012) 
and some inflammatory markers are also known to cross the blood brain barrier possibly altering 
neural cell connections (22, 49). Oxidative stress is also associated with cell death and 
differentiation and can also affect DNA methylation and gene expression (120, 123).  
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Diabetes and hypertension can also affect neurodevelopment through over-nutrition and 
neonatal hyperglycemia or under-nutrition and intrauterine growth restriction, respectively. 
Diabetes is associated with over-nutrition of the fetus often resulting in an infant that is 
macrosomic or large for gestational age (257). Larger infants are more likely to suffer birth 
complications and trauma, such as head injury and hypoxia, which can affect future brain 
development (258, 259). Infants from diabetic mothers are also at higher risk of having neonatal 
hyperglycemia, which has been associated with brain injury (260) and changes in brain 
development (179). Hypertension is associated with under-nutrition and intrauterine growth 
restriction (148), and often results in infants that are born preterm or small for gestation age 
(261). Several studies have established a connection between infants small for gestational age 
and changes in neurodevelopment (262, 263). However, it is still undetermined if there is a 
biological interaction with hypertension and growth restriction that increases the risk for ASD. 
This can be investigated in the future using SEED data that will become available with the larger 
sample size provided by additional SEED phase 2 and 3 data.  
 We observed stronger associations with pre-existing hypertension, particularly with DD. 
This may be related to the timing of the condition during pregnancy and fetal brain development. 
However, associations were also observed with preeclampsia, eclampsia, and HELLP, which 
occur later in pregnancy. These groups were not mutually exclusive and 18% of mothers with 
preexisting hypertension went on to have preeclampsia. The stronger association with pre-
existing hypertension may also be attributed to prolonged and severe conditions having a more 
harmful effect. In our study, it was difficult to assess the severity of a hypertensive disorder. One 
indicator was preterm delivery, with which we observed stronger effect estimates with 
hypertension and ASD (data not shown). However, because the recommendation for mothers 
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with sustained hypertension is to deliver early, this variable may instead remove mothers with a 
misclassified exposure. Future investigations should assess if there is a joint effect of having a 
severe condition during a critical time window in which a hypertensive mother is at higher risk 
of having a child with ASD or DD.     
We observed stronger associations in mothers with a ‘Confirmed’ condition reported in 
both the medical record and through maternal report, or in a diagnostic test. Weaker associations 
for confirmed conditions may reflect exposure misclassification or the possibility that confirmed 
cases represented more severe conditions in pregnancy. While limiting the analyses to confirmed 
condition status strengthened effect estimates, this did not change the interpretation of results for 
hypertensive disorders. However, it did strengthen the association between diabetes and DD.  
Adjusting for BMI and diabetes did not materially alter the effect estimates for 
hypertensive disorders. Previous studies have reported an interaction with high BMI and both 
maternal diabetes and hypertension (12, 166, 167). Comparing BMI stratum-specific estimates, 
we did not observe differences in the association among mothers with pre-pregnancy BMI in the 
low/normal, overweight, or obese categories. Our results suggest that weight status may not play 
a role in the association between maternal hypertension and ASD.  
Overall, our results mostly agree with other case-control studies (12, 43, 52, 163), but 
there are subtle differences that may be due to the study population and sample size, with SEED 
having the largest number of affected dyads over multiple sites in the United States. While our 
results were similar to some cohort studies evaluating this association (8, 67, 71, 165), they 
differed from others (68, 144, 166, 167). Conducting a cohort study with a rare exposure and rare 
outcome is difficult however, and most of these studies relied on registries or large 
administrative data sets that were followed over time. 
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In conclusion, we observed observations with hypertensive disorders and both ASD and 
DD. We also observed weaker associations with diabetes and DD. We hypothesize that this may 
be due alterations in fetal nutrition and development during pregnancy, which deserves further 
investigation.  
Public health implications 
Our study provides additional support that hypertension may be associated with 
developmental disorders, including ASD. This association may be present due to the effects of 
hypertension on the fetus, such as growth restriction and increased likelihood of preterm birth. 
Further studies are necessary to understand the biological mechanism through which this 
association operates. Measures can be implemented to better manage hypertensive disorders in 
pregnancy in order to mitigate environments that may place the infant at higher risk for 
developing ASD. While some hypertensive disorders are not well-managed or preventable, 
identifying hypertensive disorders as a risk factor for ASD can possibly result in earlier 
screening and better monitoring for developmental disorders. Several studies have shown the 
benefits of early diagnosis on child developmental outcomes (264, 265), and these results may 
help identify children at risk for developmental disorders earlier. 
C. Neonatal complications and ASD 
We also examined the association between neonatal jaundice and ASD. Infants with 
neonatal jaundice were identified from medical records and caregiver phone interviews. In 
addition, bilirubin measurements were available in the medical record and the Bhutani 
nomogram was used to classify infants at high risk for hyperbilirubinemia.  
Our analysis shows an association with neonatal jaundice and ASD and DD in infants 
born between 35-37 weeks gestation. The association with both ASD and DD suggests that there 
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may be a more general effect on neurodevelopment rather than on processes specific to ASD. 
There may also be an association in infants born <35 weeks, however, we had limited statistical 
power to assess this due to small sample size. We did not observe any association with neonatal 
jaundice and ASD or DD in infants born ≥38 weeks gestation. Among subcategories of neonatal 
jaundice, definite and probable jaundice were associated with ASD and DD in the 35-37 weeks 
stratum. Strong associations were not observed with possible jaundice. This may be due possible 
misclassification of the exposure among infants with possible jaundice, who were not treated and 
did not receive a diagnosis in the medical record. Or it may be due to infants with possible 
jaundice having a less severe or more transient form of jaundice. Infants with definite or 
probable jaundice may have had jaundice for a longer period of time and may have also had a 
longer hospital stay and other complications.  
  The association between jaundice and ASD among infants born <38 weeks gestation, but 
not ≥38 weeks, may be attributed to neonatal jaundice being more common and persisting for a 
longer period of time in preterm infants (253-255) and because preterm birth is shown to be 
strongly associated with ASD and DD (54, 256). Gestational age may also heavily determine 
whether an infant is diagnosed with jaundice and treated. Preterm infants may be more 
susceptible to bilirubin-induced neurologic dysfunction (BIND) at lower bilirubin levels and thus 
are treated more conservatively (266).  
Still, the health of infants with jaundice, especially preterm infants with jaundice, can be 
more complex than for term infants with no signs of jaundice There may be several unknown or 
unmeasured factors that commonly co-occur with jaundice in preterm infants that may be also 
contribute to brain development, such as other perinatal and neonatal complications and how 
they are treated or managed. Bilirubin clearance after birth requires a healthy and mature liver 
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and gastrointestinal system, and this process may be slower in preterm infants and those with 
other complications. Additionally, difficulty in feeding, that is more common in infants that later 
develop ASD, can cause neonatal jaundice and is often observed when infants have several 
complications. This presents a potential for uncontrolled confounding and should continue to be 
explored.   
We observed differences when comparing effect estimates for definite jaundice and ASD 
with ID to ASD without ID, however this difference was not observed with broader neonatal 
jaundice. Definite jaundice, defined as infants with jaundice that received treatment, was more 
strongly associated with ASD without ID, particularly in infants born <35 weeks gestation. This 
may signal a distinct etiological pathway for ASD without ID involving treatment for jaundice in 
preterm infants. However, sample sizes were small in the probable and possible jaundice groups 
and a pattern could not be established to distinguish differences in ASD with ID versus without 
ID. Due to the wide confidence intervals in the probable and possible jaundice groups, it is 
possible that patterns may emerge with larger sample sizes and may differ compared to definite 
jaundice.   
Our study is unique in our ability to also assess the association between high bilirubin 
levels and ASD/DD. While our findings with neonatal jaundice suggest an underlying 
association with bilirubin and ASD, confidence intervals were imprecise due to our small sample 
sizes. However, we did observe more precise associations with elevated bilirubin and DD in the 
35-37 weeks stratum.  Since we suspect high bilirubin levels as a biological mechanism for the 
association between jaundice and ASD/DD, we expected to see stronger associations among 
those with bilirubin levels in the 95th percentile. However, we noticed the strongest association 
with lower bilirubin levels (40th to 75th percentile) and DD infants in the 35-37 weeks stratum.  
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It is possible that infants with lower bilirubin were less likely to be treated and therefore 
could have had a prolonged exposure, but we did not have data to support an investigation of this 
explanation. Larger populations and more detailed data on exposure to elevated bilirubin are 
necessary to more precisely estimate the association and establish a causal role. We did not have 
the data to evaluate the length of time an infant had elevated bilirubin levels, but future studies 
can be designed to determine if the association we observed with neonatal jaundice and ASD/DD 
may be due to a prolonged exposure of bilirubin crossing the blood-brain barrier. 
Our results were consistent with some previous studies (105, 174, 178), but not with 
others (175-177). Differences in these results may be in large part due to differences in how 
neonatal jaundice was defined, how ASD was ascertained, which variables were adjusted for as 
confounders, or how gestational age was included in the analysis. Previous studies that included 
bilirubin levels also differed in how they defined high bilirubin. This is the first study to use the 
Bhutani nomogram to classify bilirubin levels according to time of measurement, a method that 
is recommended in current medical practice (173). In evaluating the association between 
jaundice and ASD/DD, the magnitude of the association largely relied on jaundice 
subclassification. Stronger associations were observed with definite and probable jaundice, 
which relied on a report of treatment or a diagnosis in the medical record, respectively. We 
observed weak or no associations with possible jaundice, which was defined as having jaundice 
only by maternal report. Additionally, this is the first study to account for interaction between 
gestational age and jaundice and to provide stratum-specific effect estimates by gestational age. 
Whereas other studies restricted their analyses to term infants or adjusted for preterm birth as a 
confounder.   
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In conclusion, we observed associations between neonatal jaundice and ASD and DD in 
infants born between 35-37 weeks gestation, but not among infants born at term (≥38 weeks). 
This association may be due to delayed clearance of bilirubin in preterm infants affecting brain 
development. However, there may be other unknown variables confounding this association. It is 
possible that jaundice may be one of several factors that together are associated with ASD and 
DD. Previous studies have shown associations with several perinatal complications and 
comorbidities and ASD, it is possible that these may all work jointly in altering brain 
development. 
Public health implications 
Our study indicates that neonatal jaundice may be associated with ASD and DD among 
infants born <38 weeks gestation. While the AAP recommends incorporating bilirubin 
measurement into newborn routine care, this practice is variably followed. Results from this 
study provide additional support for this recommendation. Obtaining high bilirubin levels 
necessitates immediate treatment, which may be delayed if bilirubin is not measured because 
jaundice is not visible or because the infant is born preterm with other complications. Earlier 
screening can therefore reduce exposure to dangerous levels of bilirubin.. Bilirubin levels can 
also be measured transcutaneously if jaundice is suspected following screening, without the need 
for a blood draw, which can be difficult to obtain for preterm infants. Identifying preterm infants 
that had high levels of bilirubin for a prolonged period can possibly result in earlier screening 
and better monitoring for developmental disorders. Several studies have shown the benefits of 
early diagnosis on child developmental outcomes (264, 265), and these results may help identify 
children with developmental disorders earlier. 
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D. Strengths & limitations  
The case-control study design of SEED has many advantages and disadvantages. While 
we are limited in making causal inferences or inferences about risk, the case-control study design 
allows us to evaluate the association between a rare exposure and rare outcome, such as the case 
in this analysis. Strengths and limitations from this study are discussed below.  
Selection bias 
SEED is a population-based study where potential controls were identified by randomly 
sampling birth records of children born in the specified date range to mothers that reside in the 
catchment area. However, not all who were invited to participate in the study were enrolled or 
completed the necessary data collection steps. In fact, 64% of ASD and DD families and 68% of 
POP families that were invited never responded (26). Of those that were contacted, 43% of ASD 
and DD families and 25% of POP families consented to participate (26). Our analysis also 
excluded a subset of the study sample that had an incomplete maternal interview or medical 
record abstraction. It is possible for bias to be introduced if the association between our 
exposures and ASD differs among participants and non-responders.  
It is possible that the population comparison group may not be representative of the true 
population. If this is true, then the assumption of exchangeability may not hold. In which case, 
we cannot assume that the case and control populations are drawn from the same target 
population. We observed differences between the case groups and the control group that may be 
due to study participation. For example, the control group was more likely to be White, younger, 
more likely to be educated, and less likely to smoke. While we adjusted for many of these 
variables in our analysis, if any of these variables serve as a collider in a confounding path, then 
controlling for that variable may induce bias. 
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Information bias 
Our study had different sources of data to ascertain prenatal and neonatal complications. 
These included a caregiver phone interview, abstracted medical records, mailed-in 
questionnaires, and diagnostic results from clinical and laboratory measurements from the 
medical record. While having different sources of data for one exposure may be beneficial, there 
may be discrepancies across data sources or missing data. Potential exposure misclassification 
may be present with each data source.  
While data from medical records may be more valid since it does not really on retrieving 
retrospective memories as maternal recall, present information abstracted from the medical 
records may be incomplete. For example, in many cases the abstraction form did not have a field 
to enter ‘No’ for not having a diagnosis, and medical records often record only conditions that 
exist rather than note the absence of a condition. It was therefore not always possible to 
distinguish not having a condition versus an incomplete medical record. Even if abstraction of 
the available medical record was complete, the data available to the study depended on the 
hospital and clinic sending a complete copy of the records to the study for abstraction. It was 
difficult to determine the completeness of the medical records obtained, but it is possible that 
important information regarding variables in these analyses could not have been sent. One such 
piece of information was clinical and laboratory measurements. In clinical practice most mothers 
have blood pressure measurements taken at every visit, most mothers have an OGTT after the 
24th week, and most newborns have a bilirubin measurement before being discharged. However, 
complete data on these measurements were not observed in our study.  
The caregiver interview was conducted at the time of enrollment and contained questions 
regarding the mother’s pregnancy and the neonatal period. The child was required to be 30 to 68 
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months at enrollment and is therefore possible mothers had poor recall due to long period of 
time. Factors that can affect recall can include maternal education, parity, and plurality, which all 
showed an association to our exposure and outcome groups. Because we defined exposures in 
our analyses as any report of the condition, either through maternal interview or medical record, 
it is possible that poor recall can lead to exposure misclassification that impacts study results. It 
is possible that this misclassification is differential by outcome status resulting in recall bias, 
where mothers of affected children may be more likely to search their memories and remember 
earlier events (267). 
In our first aim, we evaluated associations among ‘Confirmed’ conditions, or conditions 
that were reported in both the medical record and through maternal interview. We found much 
stronger associations among mothers with these ‘Confirmed’ conditions, which may be 
indicative of exposure misclassification due to poor maternal recall or incomplete data in the 
medical record.  
To evaluate the agreement between data sources we calculated Cohen’s kappa (κ) with 
95% confidence intervals (CI). The strength of agreement was interpreted as:  <0 none, 0–0.20 
slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 as substantial, 0.81–1 nearly perfect. We 
compared differences in agreement by outcome status, study site, maternal education, race, 
ethnicity, language spoken, parity, and events of the child’s birth. We also conducted a two-stage 
logistic regression analysis that includes an offset term to adjust for the probability of agreement 
due to chance for identifying covariates that are predictive of agreement. This method allows 
parameters to be interpreted as the true odds ratio for agreement divided by the true odds ratio 
under chance agreement. Valid standard errors were obtained using the jackknife variance 
estimator. These results showed substantial agreement for maternal diabetes and maternal 
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hypertension, but fair agreement for neonatal jaundice. The lower agreement for neonatal 
jaundice may be due to mild jaundice not receiving a formal diagnosis and delayed timing of the 
bilirubin laboratory test. It is possible that any disagreement could have been due to potential 
exposure misclassification, which can bias our results toward the null. To address this issue, we 
created ‘Confirmed’ categories for maternal diabetes and hypertension, which required report of 
the condition from two sources, and for neonatal jaundice we created ‘Definite’ (received 
treatment), ‘Probable’ (diagnosis in medical record), and ‘Possible’ (only maternal report 
available) categories.  
Mean elapsed time between data sources was 4.8 years (SD=0.68).  Medical records and 
maternal data substantially agreed on maternal diabetes and maternal hypertension, but 
agreement was fair for neonatal jaundice. For maternal diabetes and hypertension, agreement 
varied by outcome status, study site, number of children, language spoken, race/ethnicity, and if 
the pregnancy resulted in a preterm delivery (for diabetes). No difference in agreement for 
maternal diabetes and hypertension was seen by maternal education level. No factors 
significantly predicted agreement.  
For neonatal jaundice, agreement varied by the same factors as with maternal diabetes 
and hypertension, as well as method of delivery, and breastfeeding status during the neonatal 
period. No difference in agreement for neonatal jaundice was seen by maternal education level, 
preterm delivery, or NICU admission. Maternal awareness of neonatal jaundice may vary by 
severity or duration of the condition, especially if jaundice resolves without medical care. 
Positive maternal report may identify visible jaundice when bilirubin measurements do not meet 
the diagnostic criteria. Negative maternal report may identify jaundice not visible, but where 
bilirubin levels meet diagnostic criteria. Such disagreement may be reflected in our analysis, 
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where agreement was lower among infants in the third quartile of hyperbilirubin, the group most 
likely representing this situation. Only this category was significantly less likely to predict 
beyond chance agreement. The substantial agreement for perinatal conditions may reassure the 
use of only one data source evaluating the association between perinatal risk factors and 
childhood outcomes. 
Sample size 
The case-control study design increases statistical power to detect associations with a rare 
outcome. In our study, we were able to detect associations with prenatal and neonatal 
complications and ASD with fairly precise confidence intervals. While we had sufficient sample 
size for main effects, some associations among sub-classifications of the exposures and outcome 
show imprecise results. However, some of these associations were strong enough to reach 
statistical significance. Yet, it is possible that some spurious associations may be observed due to 
small sample size. Further studies should be conducted in larger sample sizes to confirm 
associations between subclassifications of maternal diabetes and hypertension, and ASD. The 
association between neonatal jaundice and ASD should also be evaluated in a study sample with 
a larger preterm population.  
Strengths  
The SEED population-based study design is specifically tailored to identify etiologic 
factors contributing to ASD. SEED is also a multi-site study and generalizable to the U.S. 
population, with sites in different regions of the U.S., two of which recruited Spanish-speaking 
participants. The study has two comparison groups to distinguish if etiological factors are 
specific to ASD or broader neurodevelopment. The case-control study design of SEED is ideal 
for investigating rare outcomes such as ASD and DD. The large SEED population made it 
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possible to assess for interaction and provided stratum specific estimates for the association 
between jaundice and ASD. 
Defining conditions from either the medical record or maternal report could have lead to 
exposure misclassification, but it also reduced the possibility of halving false negatives for the 
exposure. In addition, we found good agreement between data sources to confirm their validity. 
Data from the medical record was abstracted from clinical notes and measurements, not just 
ICD9 codes that could be used to refer a patient for testing. For the first aim, we were also able 
to address validity by creating a subclassification for a ‘Confirmed’ condition where medical 
record and maternal report were in agreement and removing those without a confirmed condition 
from the dataset. For the second aim, we created subclassifications based on if a case was 
considered ‘Definite’ (treated), ‘Possible’ (medical record diagnosis), or ‘Probable’ (only by 
maternal report). These subclassifications require a greater level of detail on exposure status that 
is not available in other studies. 
One of the greatest advantages of SEED is the in-person assessment conducted to 
confirm ASD using the ADOS and ADI-R, the gold standard instruments for ASD diagnosis. 
Clinical evaluation reduces outcome misclassification compared to other studies that use school 
records, ICD-9 codes, or administrative datasets to classify a child as having ASD or DD. 
Children in the DD and POP group were also screened, reducing outcome misclassification by 
evaluating undiagnosed children. 
E. Future directions  
Results from this study show an association between prenatal and neonatal conditions and 
ASD and DD. Further studies are needed to determine whether these associations are causal, or if 
other covariates involved are influencing these observations. One main area for future study will 
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be to determine if there is a difference in association with complications that are chronic versus 
acute. In specific aim 1, we observed a stronger association with preexisting/chronic 
hypertension. And in specific aim 2, we observed a stronger association with bilirubin levels that 
were elevated, but not enough to warrant treatment. Both of these findings suggest that a chronic 
condition may have a stronger effect on neurodevelopment. However, our study was limited in 
determining how long a condition was present. Future studies involving more clinical 
measurements over time, such as serial blood pressures and transcutaneous bilirubin, can 
evaluate the effect of a prolonged exposure. These studies can also help establish sensitive time 
windows for environmental exposures associated with ASD.  
Preterm birth was an important variable to consider in our studies. In specific aim 1, it is 
strongly associated with maternal hypertensive disorders. And in specific aim 2, we observed an 
interaction between preterm birth and neonatal jaundice. It is difficult to determine in these cases 
whether the causal pathway operates through more severe complications or preterm birth, or a 
combination of the two. Further studies can be conducted in preterm populations to identify 
biological mechanisms by which environmental exposures are associated with ASD.  
And finally, future studies should evaluate the feasibility and benefits of conducting early 
screening for ASD based on results from this study. Targeting early intervention and 
developmental service programs to children that are born to hypertensive mothers, born preterm, 
or with confirmed neonatal jaundice could result in early identification of ASD or DD. However, 
studies are needed to confirm this. 
F. Conclusions 
The observations reported here provide further evidence that prenatal and neonatal 
complications may have a role in the development of ASD and DD. These observations also 
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support the role of preterm birth in conjunction with these complications, and merit further study 
on these potential risk factors. 
Continued work to identify specific risk factors for ASD is necessary, many other less 
common prenatal and neonatal complications may also be associated with ASD. Together, these 
studies can help elucidate the etiology of ASD. Identification of modifiable risk factors can help 
reduce the prevalence of ASD, or can increase early diagnosis and early treatment.  
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